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ABSTRACT
NON-PARAMETRIC ALGORITHMS FOR EVALUATING GENE EXPRESSION
IN CANCER USING DNA MICROARRY TECHNOLOGY
by
Virginie Aris
Microarray technology has transformed the field of cancer biology by enabling the
simultaneous evaluation of tens of thousands mRNA expression levels in a single
experiment. This technology has been applied to medical science in order to find gene
expression markers that cluster diseased and normal tissues, genes affected by treatments,
and gene network interactions. All methods of microarray data analysis can be
summarized as a study of differential gene expression. This study addresses three
questions, 1) the roles of selectively expressed genes for the classification of cancer, 2)
issues of accounting for both experimental and biological noise, and 3) issues of
comparing data derived from different research groups using the Affymetrix GeneChip Tm
platform. A key finding of this study is that selectively expressed genes are very
powerful when used for disease classification. A model was designed to reduce noise
and eliminate false positives from true results. With this approach, data from different
research groups can be integrated to increase information and enable a better
understanding of cancer.
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CHAPTER 1
INTRODUCTION
1.1 Cancer Background
The term cancer encompasses many conditions charactenzed by uncontrolled
proliferation of cells. Almost all organs and cell types can undergo oncogenic
transformations, with an array of mechanisms and outcomes. Cancer anses through a
succession of events making it more preeminent in the aging population. The causes are
many and vaned including: genetic predisposition, environmental influences, diet,
cigarette smoking, infectious agents and aging. The complexity and diversity of the
regulatory and downstream effector pathways affected by cancer has hindered the
development of effective and specific therapies.
Cancer accounts for 23% of the deaths in the United States annually. It is the
second leading cause of death behind heart disease (Jemal et al., 2003; Simmonds, 2003).
Approximately 1,334,100 new cases of invasive cancer were diagnosed in 2003, more
than one million cases of squamous cell skin cancer, 55,700 cases of breast carcinoma,
and 37,700 cases of melanoma. An estimated 556,500 people died from cancer in 2003.
The three most commonly diagnosed cancers for men are: prostate (33%), lung (14%),
and colon (11%). For women, the three most commonly diagnosed cancers are: breast
(33%), lung (12%) and colon (11%). The leading causes of cancer deaths are the same
three as above for each gender. More specifically, lung cancer surpasses all other cancers
in terms of fatalities being responsible for 31% of the death by cancer for men, and 25%
for women. Prostate cancer accounts for 10% of the cancer death toll for men, and breast
1
2cancer accounts for 15% of the death by cancer in women. Colon cancer accounts for
10% of the deaths for men and 11% for women. Cancer is the pnmary cause of death
among women aged from 40 to 79 and men aged from 60 to 79.
Due to early detection through increased screening, the survival rate has increased
and the death toll decreased slightly in the last few years (Black and Welch, 1993).
Eighty-five percent of the prostate cancers are diagnosed at the local or regional stage
with a five-year survival rate of 100%. Unfortunately, most cancer therapies have a
limited efficacy when the disease is treated in its later stages.
To improve survival, the key points are: 1) early diagnosis 2) more effective drugs
to treat later stages 3) a better prediction of the treatment response and 4) chemo-
prevention of tumorgenesis (Ochs and Godwin, 2003). Biomarkers can help with all
those key points. Gene expression markers, by definition, are genes that are consistently
up-regulated or down-regulated in cancer samples compared to normal samples. The
hypothesis is that the consistency is the sign that the genes in question are part or
downstream of regulatory pathways necessary for tumorgenesis. Gene markers are
obviously important for early diagnosis and can help define the therapeutic course of
action i.e. treatment for tumor with hormone receptors in breast cancer (Shenkier et al.,
2004). Biomarkers can become targets for drug development and can help predict
treatment response. A detailed study of their function might explain the events leading to
their de-regulation and help to design chemo-prevention therapies. Two factors are
important in identifying biomarkers: the ability to define the cancer group and subgroups
and the use of high-through-put methods such as microarray technology to discover genes
3that are consistently up-regulated or down regulated. The second issue is discussed in
this dissertation.
The normal cell can be viewed as a system in which functions are tightly
regulated. There are even fail-safe and redundant checks balances to ensure that the cell
functions the way it should. In contrast cancer cells present an accumulation of
replication disorders ansing through gradual accumulation of genetic changes. Typical
cancer cells contain combinations of genetic changes that alter gene expression causing
the cell to escape the checks and controls that prevent proliferation and metastasis. A
single mutation event is generally not enough to circumvent all the different safeguards a
4complex organism has built in. Instead, two or more sequential events are needed to
initiate the transformation of a normal to a malignant cell (Vogelstein and Kindlier, 1993).
Cancer is thought to anse from the clonal proliferation of a single cell, requinng
the activation of the cell cycle and the overnding of some cell functions, in particular the
cell death program (apoptosis). Dunng proliferation, mutations, deletions and
amplifications of chromosomes occur due to genomic instabilities. Specific cellular
malfunctions associated with cancer are the loss of the tumor suppressor p53 gene (Sherr,
2004) thereby preventing apoptosis, the gain of function or amplification of the cell
growth regulators such as c-KIT (Muller-Tidow et al., 2004), and the activation of proto-
oncogenes such as c-MYC (Nilsson and Cleveland, 2003). Dunng these changes, the
RNA levels of other genes are also affected, thereby disturbing the normal cellular
equilibnum within the background of the other process and stochastic events. The cell as
a result obtains another state of equilibnum in which it becomes "immortal".
Specifically, it becomes independent of its environment for survival and proliferation.
However, this is not enough for the development of a solid tumor. Many people carry in
situ tumors, that are very small and do not develop into disease (Folkman and Kallun,
2004). In order to proliferate, tumors need to recruit their own blood supply through
angiogenesis (Hanahan and Folkman, 1996).
A major problem when studying a few genes in a pathway is that these genes are
also influenced by others omitted in the study. This results in sometimes inconsistent
findings where the same perturbation can lead to two different outcomes in different
cells: i.e. over-expression of Myc can lead to cell proliferation or cell death (Nilsson and
Cleveland, 2003). The knowledge of pathways is too incomplete to omit the other genes.
5To be able to comprehend cancer, a global approach at the genome expression level must
be taken. Microarray technology is particularly well suited for this holistic approach as it
analyzes the expression of thousands of genes at the same time.
Genetic changes associated with cancer can involve chromosomal deletion,
amplification, mutation, or deregulation of expression. Cancers can nse from a multitude
of cellular events, and have very heterogeneous genetic changes. Cancer cells that seem
histologically identical may respond differently to therapy, and may evolve very
differently from indolent tumors to invasive metastatic tumors. Many of these changes
can be observed at the mRNA level. Current cancer classification techniques and
treatment decisions rely on subjective judgments of tumor histology by pathologists.
Multiple DNA microarray studies have been proven useful for classification (Golub et al.,
1999) and prognosis (Shipp et al., 2002; van 't Veer et al., 2003; van 't Veer et al., 2002).
Global analysis of gene expression will allow classification of morphologically similar
human cancer and will help tailor treatment maximizing the therapeutic effect and
minimizing the toxicity (van 't Veer and De Jong, 2002). Another way microarray data
can help treatment of cancer is through the screening of new drugs. It should be possible
to observe the effect of a drug on gene expression profiles and create a model to predict
the expected therapeutic response (Hughes et al., 2000).
However, the holistic approach of using microarray technology has brought up
some issues. In addition to the significant cost of performing microarray expenments,
there is a signal to noise issue as most genes are not involved in the processJcondition
studied. Also problematic, on the hardwareJsoftware level, are the data storage and the
handling of large datasets. In order to be able to save the information in a format that can
6be mined, databases and standard annotations were created. Also data analysis packages
and methods were developed to handle the amount of data collected. Another limitation
of microarray technology is the punty of the sample. Tumors are a mixture of
heterogeneous cell types with malignant cells at different stages of differentiation, normal
epithelial cells, blood vessels and cells involved in the inflammatory process. This mix
can mask the differences from one cancer to another. Laser-capture-microdissection
resolves this problem but creates the need to amplify the RNA sample to be able to detect
the different mRNAs, with the nsk of introducing bias in the measurements.
Once produced in a cell, RNA is stabilized, spliced, polyadenylated, exported
towards the cytoplasm, translated into proteins and ultimately degraded (Lodish et al.,
1995a). The regulation of mRNA decay rate is important for determining transcnpt
abundance. The decay rate of individual mRNAs vanes greatly form a short half life of a
few minutes to half lives spanning several life cycles (Hernck et al., 1990; Wilusz et al.,
2001). This difference may be important if samples are not processed in a consistent
manner. Another unresolved issue in microarray data results is the effect of cross
hybndization. This phenomenon occurs when there is non specific binding or binding of
related sequence to the wrong microarray probes. This affects greatly the estimated
mRNA levels.
71.2 Tools Available for Cancer Study at the DNAIRNA Level
Many tools were available to the study of cancer before the advent of microarrays. Most
of our knowledge about cancer today still stems from expenments done with traditional
techniques. The most utilized techniques for discovenng mutations at the genome level
are Fluorescence In Situ Hybndization (FISH) and Comparative Genomic Hybndization
(CGH). Fluorescence In Situ Hybndization analysis uses either whole chromosome
probes or specific probes to label chromosomes and see if there is any obvious deletion or
amplification of the genetic matenal. Using this method, gain or loss of chromosomes
can be shown (Bernell et al., 1998). Comparative Genomic Hybndization also helps
detect regions of gain or loss of DNA at the genomic scale. The DNA of a cancer cell
and a normal cell in metaphase, are labeled with a different fluorochrome and hybndized
to each other. Differences in the ratio of intensity of the two fluorochromes along the
chromosomes, helps detect the regions where amplification or deletion occurred
(Kallioniemi et al., 1992).
Another commonly used technique for looking at DNA mutations is Restnction
Fragment Length Polymorphism (RFLP). Initially DNA is digested into fragments using
a cocktail of restnction enzymes and then run on a gel. By studying multiple samples on
a gel, one can find particular fragments (bands) that are specific to either normal or
cancer samples (Dracopoli et al., 1985). Once such markers are found, the gel "bands"
can be cut out and sequenced to find out the identity of the genes involved. A denvative
from this technique the amplified restnction fragment polymorphism (AFLP) has an extra
step of amplification after the restnction of the DNA, helping with the issue of small
sample amounts. A vanant, the cDNA-AFLP first transcnbes the mRNA into cDNA and
8then the standard AFLP protocol is applied (Bachem et al., 1996). This last technique
allows the identification of multiple differentially regulated transcnpts at a time.
Another method designed to locate a particular sequence of DNA within a
complex mixture is the Southern blot, named after Edward M. Southern. The method is
as follows: first DNA fragments are separated by electrophoresis on an agarose gel, then
the fragments are transferred (blotted) onto a membrane, the membrane is then soaked in
a solution with a labeled probe of sequence complementary to DNA that needs to be
located, and then after washing and imaging one can see if the particular sequence sought
was in the sample (Southern, 1975).
The major techniques to study mRNA expression levels are: Northern blotting, in
situ hybndization and quantitative PCR. The Northern blot uses the same basic concept
as Southern blotting on RNA. This method locates specific sequences that the
expenmenter has a probe for. Even though one can look at a few samples at a time, only
two genes are usually probed: the gene sequence of interest and one for a control
sequence (Actin, GAPDH). In situ hybndization helps locate the intracellular
localization of a specific mRMA or protein (Korabiowska et al., 2004). For this, a
radioactively labeled probe is hybndized to a fixed cell, and the result is developed on x-
ray sensitive film. Quantitative polymerase chain reaction (PCR), after reverse
transcnption of mRNA into cDNA, can help find if a particular mRNA is present in the
sample (Kondo et al., 1992; Myers and Gelfand, 1991). An improvement of this
technique: the quantitative real-time PCR, is the most precise technique so far for the
quantization of mRNA (Bernard and Wittwer, 2002; Mocellin et al., 2003).
9With the sequencing of the human genome, more genes and predicted gene
sequences are now available. This changes the approach of molecular biology from the
study of a single gene to the study of a system of thousands of genes. The Senal
Analysis of Gene Expression (SAGE) amplify tag sequences from known and unknown
genes, and sequences them (Velculescu et al., 1995). The advantages of this technique
are many, the instrumentation cost is small if the facility already has a sequencer and it
isolates and quantitates known and unknown transcnpts. The disadvantages are also
numerous as some of the tags are not specific to one gene and might differ in length
posing problems when analyzing the sequenced concatenated tags.
Another very powerful method to select differentially regulated mRNA and
isolate rare mRNA species is the subtractive hybndization technique (Lee et al., 1991).
The mRNA from the investigated cells is reversed transcnbed into cDNA. Common
mRNA sequences between the studied cells and the chosen standard are subtracted. The
standard cells have their mRNA reverse transcnbed and biotinylated. cDNA that
hybndize to the mRNA of the studied cells and are separated from the rest of the mRNAs
by binding to streptavidin. The resulting subset of subtracted mRNA is then cloned into a
library for further screens and investigation. This powerful method is very lengthy; two
to three months of work is required in order to obtain a subtracted library.
DNA microarrays are rapidly becoming a fundamental tool in genomic research.
Publications based on microarray findings increase each year (Ochs and Godwin, 2003).
This technique is fast; less than a week is needed from isolation of the RNA to the
acquisition of the results, and multiple samples can be processed at the same time. The
descnption of the technology is going to be explained in detail in the next section.
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1.3 Microarrays: The Fundamentals
Deoxynbonucleic acid (DNA) is the cellular molecule that carnes the information
required to build a cell or an organism. This information is transcnbed into nbonucleic
acid (RNA), which carnes the instructions from the DNA for the correct amino acid
sequence to synthesize proteins, the main effectors of cellular functions. Proteins are
involved in cell processes from DNA replication to the regulation of cell structure and
function. Proteins can be regulated by a tightly controlled production,
activationJinactivation and degradation in the cell. Ubiquitinization and degradation of
mRNAs can also lead to a regulation of the amount of proteins in a cell. The cell has a
tight quantitative and qualitative control on transcnption of genes (DNA -+ mRNA).
These messenger RNA levels in a cell can give an indication of which proteins in the
cells are being produced at the time of sampling and can also reflect changes in the
genetic code due to disease (Lodish et al., 1995b). Cancer cells can have deletion or
amplification of DNA resulting in change of gene expression. Gene expression can also
be modulated through methylation or mutation of the promoter sequence, deregulation of
transcnption factors (Jones, 1996; Lodish et al., 1995b).
The DNA microarrays technology estimates the amount of mRNA for thousands of genes
at the same time in contrast to the "one gene in one expenment" approach. An array
consists of an orderly arrangement of gene specific poly-nucleotides strand that match
known and unknown nucleotide strands of DNA (i.e. human, rat...). There are design
considerations in choosing the oligonucleotides for hybndization on microarrays. First,
the oligonucleotides must have a common thermodynamic profile of melting temperature,
in order to properly hybndize or bind to the target while reducing non-specific binding.
11
As the melting temperature increases with the length of the oligonucleotides and GC
content, the hybndization temperature will have to be adjusted depending on these
factors. A second consideration is to avoid probe that might form secondary structures
preventing the hybndization of the target. And the last consideration is to find probe that
are not homologues to other sequences. As the probe length shortens, there is an increase
in the probability to find an homology to another sequence. A 75-80% homology or
more than 15 continuous complementary bases in non targeted sequence will produce a
false signal as it hybndizes partially to the probe. One way to remedy this is to use
BLAST' software to select probes in parts of the genes that do not have homology to
other genes. These considerations are the same as the ones for designing PCR pnmers.
Temperature and salt concentration can be optimized for a given set of pnmers for PCR,
but with microarrays these conditions need to be the same and close to optimal for
thousands of probes at the same time.
Two microarrays technologies are dominating the field: the Affymetrix GeneChip
(Lockhart et al., 1995) and the in-house pnnted arrays (Schena et al., 1995).
1.3.1 AffymetriD GeneChip Technology
Affymetrix GeneChips are manufactured by synthesizing oligonucleotides of defined
sequences on a glass substrate chip. The synthesis technology is a light directed solid
phase DNA synthesis. This technique allows the synthesis of tens of thousands of unique
oligonucleotides per square centimeter on a glass surface (Fodor et al., 1991). A probe
cell is a specific area on the chip containing millions of copies of a specific 25-nucleotide
http:JJwww.ncbi.nlm.nih.govJBLASTJ March 2004
12
long oligonucleotide. Arrays are manufactured in a series of cycles represented in Figure
1.2. The glass substrate is first coated with linkers containing photolabile protective
groups. Then, a mask is applied exposing selected portions of the probe array to
ultraviolet light which removes the photolabile protecting groups. This enables selective
nucleoside phosphoramidite addition only at the exposed sites. This is repeated to allow
specific sets of oligonucleotide probes to be synthesized for each probe cell.
Labeling of the RNA sample is achieved by first reverse transcription of the
mRNA into cDNA and then into cRNA through in-vitro transcription with biotin labeled
nucleotides. The cRNA is then fragmented and hybridized overnight onto the probe
array. The hybridized probe array is then stained with streptavidin phycoerythrin
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conjugate and scanned with a laser emitting a wavelength of 488 nm and the amount of
light emitted at 570 nm is recorded as proportional to the bound target (Figure 1.3). The
signal can be amplified with a second round of staining with goat anti-streptavidin
antibody and biotinylated Goat IgG.
These arrays are able to measure the absolute expression of genes in cells or
tissues with the precision of one transcript in 1,000,000 (Lipshutz et al., 1999). The
disadvantages of the Affymetrix GeneChip technology are a high cost per array and the
inability to compare two samples on the same chip rending comparison susceptible to
normalization processes.
Figure 1.3 Labeling of the RNA sample and hybridization of the Affymetrix GeneChips.
The RNA sample is transcribed into double stranded eDNA using a T7-oligo dT primer.
After clean up and in vitro transcription is performed using a T7 RNA polymerase and
biotin labeled nucleotides, the cRNA is then fragmented and hybridized overnight onto
the probe array. The hybridized probe array is then stained with streptavidin
phycoerythrin conjugate. A second round of staining with goat anti-streptavidin antibody
and biotinylated Goat IgG is used to amplify the signal received when scanning.
(Figure courtesy of Affymetrix, Inc.)
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1.3.2 Spotted Microarrays
The other widely used technology is the spotted microarray. Synthetic oligonucleotides
or PCR products derived from cDNA are spotted onto a microscopic glass slide coated
with poly-L-lysine, Amino Silane, Super Amine, or Super Aldehyde. Those arrays are
usually printed using a high density arrayer (Cheung et al., 1999). Spatial resolution of
the arrayer determines the density of the array. Most instruments use pins or needles to
transferJspot oligonucleotides or cDNA probes from 96 or 384 microtiter plates. The pin
shape, diameter and the spotting solution determine the size of the spot on the array. The
final array is no bigger than 3 square inch and the spot diameter is of the order of 0.1mm
to 70 microns. The labeling of total mRNA is typically done by synthesizing single
stranded DNA with a reverse transcripts incorporating nucleotides with a fluorescent
molecule attached to them. Cyanine 3 and Cyanine 5 dUTP are the most commonly
incorporated fluorescent molecules. Two samples, each labeled with a different dye are
hybridized to the array (usually overnight). Labeled gene products bind to their
complementary sequences in the spots. The array is then washed and the dyes enable the
amount of sample bound to a spot to be measured by the level of fluorescence emitted
when excited by laser. From the fluorescence intensities in the channels scanned for each
spot, the relative expression levels of the genes in both samples can be estimated.
Spotted microarrays are usually analyzed with the ratio of relative expression between the
samples hybridized on the slide.
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1.4 Summary
Microarray technology is a powerful tool to analyze the changes at the mRNA levels in
cancer. This technology allows the analysis of thousands of genes in a single experiment
in less than a week. It is thus considered to be the best technology to find gene
expression markers in cancer. However the development of microarrays has preceded
statistical methods for analysis of the results. Major problems due to signal estimation,
normalization, and multi-testing are still the topic of many publications each year.
CHAPTER 2
CURRENT STATUS OF M1CROARRAY DATA ANALYSIS
The use of microarrays has become common in biological sciences. The query "DNA
microarray and cancer" yielded 226 papers in the literature search engine Pubmed 2. In
this Chapter, the different steps and methods in the analysis of microarray data are going
to be presented. First, a signal intensity has to be extracted from the image for each
geneJfeature and the transcript expression level has to be estimated. Then, the results
from each array have to be normalized in order to be able to compare the results from one
array to another. Finally, analysis methods can be applied to find the genes that are
differentially regulated between conditions.
2.1 Image Analysis and Signal EDtraction
For both types of microarray, a specialized scanner is used to asses the hybridization
signal. Analysis of gene expression data is usually done in a two-step process: image
processing and data analysis. There has been a plethora of techniques and software
developed for detecting and delineating the target spots on the array, eliminating
background from the intensity, correcting for bias due to different dye affinities, and
scaling or normalization in order to compare multiple arrays (Bolster et al., 2003; Li and
Wong, 2001a; Quackenbush, 2002; Yang et al., 2001). These techniques are usually
specific to the array platform although some correspondence can be drawn between them.
2 http:JJwww.ncbi.nlm.nih.govJentrezJquery.fcgi March 23 rd 2004
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For spotted arrays, cDNA or oligonucleotides corresponding to the
complementary sequence of the cDNA obtained by in vitro reverse transcription are
deposited on slides as spots. A lot of emphasis has been placed on the featureJspot
recognition with different ways to identify the arrayed spots on the chip and measure the
background. In most cases the spots are circled and the pixel intensities for each
wavelength within the circle are averaged, or a median is taken, and intensities outside
the circle are also averaged for local background estimation i.e. GenePix® Pro 4.0 from
Axon Instruments Inc. A newer version of this software allows the delineation of spots
that are not shaped into circles (GenePix® Pro 5.0). Another software package,
ImaGene® from BioDiscovery Inc. allows the detection of pixel artifacts inside the spots
and removes them from the intensity estimation of the spot. There are multiple software
packages and methods for extracting the signal intensity. Future software must place
more emphasis on the quality assessment of spots and arrays. In the image processing
step, the quality of the printing, the alignment of the grid, the annotation, and scanner
calibration are essential for the reproducibility of the experiment (Johnson and Lin,
2003).
Affymetnx GeneChips are hybridized with only one sample per chip. The
dynamic intensity of the probes range from 0 to 65,000. As the oligonucleotide sequence
is short: 25 nucleotides, a gene is represented by a probe-set composed of a series of
preferably non-overlapping nucleotides. A probe set, usually contains between 16 to 20
probe pairs. A probe pair is composed of 2 probe cells. One of the probe-cells contains
DNA sequences complementary to specific mRNA sequences and is called the perfect
match probe or PM probe. The other probe cell is composed of an oligomer identical to
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the PM probe except for a single base difference in the central position (mismatch or MM
probe). The mismatch probe is used to estimate the background hybridization. Many
different software packages have been developed for the estimation of gene intensity.
The Microarray Analysis Suite 4.0 (MAS 4), produced by Affymetrix Inc, is empirical in
nature (Affymetrix, 2000). Subsequently a model-based estimate for the expression
levels of genes (MBEI) was designed by Li and Wong, in 2001, as an alternative to MAS
4. In 2002 Affymetnx Inc. released a new version of its Microarray Analysis Suite, MAS
5, based on statistical algorithms (Affymetrix, 2001; Affymetrix, 2002a; Hubbell et al.,
2002). Another method called robust multi-array average (RMA) was developed in Dr.
Speed's lab (Irizarry et al., 2003), and is basically a PM only model with a local
background subtraction. These commonly used techniques are reviewed in the following
sections.
2.1.1 MAS 4
The MAS4 software first extracts the intensity for all probe cells by aligning a grid to
match the delimitation of the features and then averages the pixel intensity within a
delineated probe cell (Affymetrix, 2000). With MAS4 the Average difference (Avg Diff)
is calculated for each probe set as the average of the differences between every PM probe
cell and its control MM probe cell. This is considered to be directly related to the level of
expression of the transcript. However, this method can give negative values for a probe
set if there is more hybridization signal in the mismatched sequences than in the perfectly
matched ones. The software also estimates the presence or absence of each transcript by
giving an absolute call using a decision matnx. For example, in order for a gene to be
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called present, the positive fraction, number of time PM>MM in the probe set divided by
the number of probe pairs used, has to be above 0.43, the ratio of positive to negative
probe pairs has to be above 4.0 and the Log Avg Ratio of the PM to MM intensities for
each probe pair has to be above 1.3. All these default threshold values have been
established through empirical testing (Affymetnx, 2000).
2.1.2 MAS 5
The updated version of MAS 4.0 released in 2002 and designated Microarray Analysis
Suite 5.0 (MAS 5) uses a statistical inference of the signal of a transcript and its presence
or absence insteer of an empirical one (Hubbell et al., 2002). Their detection call is
based on the Wilcoxon signed rank test to determine whether the discriminant score
(R=(PM-MM)J(PM+MM)) of the probe set is greater than 0.015. For the expression
value, if few MM probe intensities exceed the PM probe intensity in the probe set, the
algorithm creates an adjusted MM value based on the average difference intensity
between log2PM and log2MM. When most of the MM probe intensities exceed the PM
value, the adjusted MM value is set to some fraction of PM and the transcript is
considered absent. This eliminates the negative signal. Then MAS 5.0 uses the One-Step
Tukey's Biweight Estimate as a quantitative measure of the mean mRNA abundance for
each gene. This weighted estimate is less sensitive to outliers. The log of the
background-erjusted PM-MM difference for each probe pair is weighted by its distance
from the median value for the entire probe set. The weighted log(PM-MM) values are
then used to calculate the overall mean of the probe set. The signal output in MAS 5 is
this adjusted mean converted back into linear scale.
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2.1.3 MBEI
Li and Wong designed, in 2001, a model-based estimate for the expression levels of
genes as an alternative to MAS 4. They observed using an Analysis of Variance analysis
(ANOVA) that the residual mean squares at the probe level is greater than the ones
between replicate arrays. Their model accounts for this probe variability. For 1 arrays
hybridized with different samples, each gene has J probe pairs (10-16 depending on the
arrays) associated with it, giving x(2xJ) probe intensities ( PM + MM) intensity values.
They assumed that the intensity for a particular probe increases linearly with the
concentration of the transcript in the sample, that this rate of increase can be different
from one probe to another, and that the rate of increase is higher in the PM probes instead
of the MM probes (Li and Wong, 2001a). With Oil representing the concentration of a
transcript in the ith sample they formulated the following model for the PM and MM
intensities:
bb represents the background intensity for jth probe, ail the rate of increase of the jth MM
probe due to non specific hybridization, i is the specific rate of increase for the jth PM
probe due to the target concentration in the sample and & represents random error
following a normal distribution N(0,62). By subtracting the MM intensities from the PM
we obtain:
The average difference is a linear function of the target concentration plus or
minus a random error. Given replicate data, we can estimate the mean and standard
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errors of the 0 and 9 of each probe set. Given the standard error, we can identify outlier
arrays and probes and exclude them from the analysis for the estimation of the target
concentration. They also noticed that cross-hydridization is more likely to occur on the
MM probes than with the PM probes. The target not only hybridizes to the PM probe but
also cross-hybridizes with the MM probe. They erded an option to the dChip 1.1 program
for a PM-only model (Li and Wong, 2001a), which is more robust to cross-hybridization
than the PM-MM difference model as it does not subtract the MM probe to the PM signal
intensities.
The PM-only model estimates the expression value 0 and the probe sensitivity
index (PSI) 9 using an iterative algorithm, and eliminates the outliers using the same
method as the PM-MM model. The Li and Wong model was found to give a more
accurate estimation of the signal intensity than the Average Differences given by the
Affymetrix MAS4 software (Lemon et al., 2002). However, Rajagoplan demonstrated
that the dChip algorithm gave inferior results than MASS for estimating true changes and
presented a higher percentage of false positive on the Latin square dataset (Hubbell et al.,
2002; Rajagopalan, 2003). He also found the dChip algorithm PM only to be very weak
at estimating lower target concentrations because it does not subtract the background
hybridization.
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2.1.4 RMA
The Robust Multi-array Average (RMA), developed in Dr. Speed's lab (Irizarry et al.,
2003), corrects the arrays by first using a signal dependant background estimate, then
normalizes the arrays using quantile normalization and then fits each normalized, log2
based background corrected probe set to a linear model:
Where aji is the probe affinity effect for the probe set n, IA represents the log scale
expression level for array i, and ii is a random error (with a mean of 0). They use a
median polish method to estimate the parameters in a robust manner. This method is
available in the Bioconductor package, an open source and open development software
project for the analysis and comprehension of genomic data (Ihaka and Gentleman,
1996). The authors showed that RMA reduced the variance and bias compared to MASS
and Li and Wong PM-MM model (Irizarry et al., 2003). It also showed greater
sensitivity in detection of differential expression.
2.2 Normalization Strategies
After image processing, it is necessary to normalize the data obtained, in order to
compare the different sample intensities. In the GeneChip system, samples are
hybridized on different chips and normalization is applied to enable comparison of one
chip to another. For spotted arrays, two samples are labeled with different dyes resulting
in a need to do a within-chip normalization to eliminate bias due to uneven starting RNA
level, difference in labeling efficiency due to a dye bias or RNA quality, and systematic
bias when measuring the expression levels.
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GeneChips are frequently normalized using a global scaling procedure. Every
gene-expression value is multiplied by a constant so that the median intensity on the array
equals a set threshold. Affymetrix MAS 4 trims the top and bottom 2% of intensities in
order to take a more robust mean measure. MAS 5 uses a global normalization to a set
baseline intensity and perturbs it by multiplying or dividing by 1.1. This helps overcome
the fact that a normalization factor does not necessarily fit all the probe sets. A related
approach in spotted arrays is to fit the two color intensities on a line with a slope of 1 and
an intercept of 0. These approaches rely on the fact that a cell will express about the
same amount of RNA at any given time or conditions, and that most of the genes
expressed are not changing. This assumption might not be true in a lot of cases, for
example, if you compare different cell types that expresses less RNA than the other or if
the treatment has an effect on the production or degreration of RNA. Another problem
with the global scaling is that it does not account for the non-linearity of the data. The
highly expressed RNA levels might need a different scaling factor than the lower
expressed ones. This can be seen when plotting the intensities of the two samples (two
Genechips, or one two color spotted) against each other and the result has a non linear
trend, and in the case of most spotted array a bias towards the Cy3 in the low expression
range (green tail). In order to better see the bias, one can use an M-A plot (Dudoit et al.,
2000) where M represents the log ratio of the two dyes; M=log (Cy5JCy3), and A is the
average of the logarithm of the intensities; A=[log (Cy5)+log (Cy3)]J2. This plot is a
rescaled 45-degree rotation compared to Cy3 plotted against Cy5. In the case of no bias,
one should see an even scatter of the spots around zero on the x-axis. If the bias is
24
intensity dependant, the cloud of points will not be evenly distributed and will have a
curved shape.
To correct for the non linearity of global scaling approach, non linear scaling
methods (Li and Hung Wong, 2001; Li and Wong, 2001a); (Stuart et al., 2001) can be
performed with the assumption that an "invariant set" of genes exists, and that their rank
in expression within a chip does not change significantly. They use this invariant set for
the non-linear regression at either the feature (Li and Hung Wong, 2001; Li and Wong,
2001a) or the probe set level (Stuart et al., 2001). This method corresponds roughly to
the Lowess normalization used on spotted microarrays; the genes found in the invariant
set follow the Lowess normalization curve (Yang et al., 2002b). The global
normalization Lowess (Dudoit et al., 2000; Quackenbush, 2002; Yang et al., 2002a; Yang
and Speed, 2002) performs a locally weighted linear regression as a function of the
log(Cy3* Cy5) and correct the log ratios to an average of zero in that local region. This
method performs a linear approximation of a non-linear regression. The user can define
the fraction of data used for smoothing each point, usually 40%, rendering the linear
approximation robust to a small percentage of differentially expressed genes. Another
variant of this method uses a rank invariant method to select the genes that are not
differentially expressed and applied the Lowess normalization to the chip using this set of
genes (Tseng et al., 2001). This algorithm can also be applied locally to each sub arrays
produced by individual pins, correcting for spatial variation such as gradient and
differences between the pins (Yang et al., 2002b).
Another approach is to scale to a set of controls that can be either genes whose
expression is not affected by the treatment or spike-in controls. The problem with these
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methods is that: 1) there is no gene whose RNA levels never fluctuate, 2) spiking RNA or
DNA is subject to pipeting errors and the end result may not correlate with the quality of
the RNA that influenced the hybridization.
The normalization procedure has a greater effect on the subsequent detection of
differentially expressed genes than was anticipated in the past (Hoffmann et al., 2002).
In their study Hoffman et al., 2002, found that the effect of the normalization was greater
than the effect of the analysis algorithm for finding differentially expressed genes.
2.3 Analysis of AffymetriD GeneChips
Analysis methods for microarray data can be classified in two categories: supervised and
unsupervised learning. Unsupervised methods can be applied without the prior
knowledge of the sample states: i.e. cancer or normal. They identify patterns in the gene
expression profile and group similar samples together. For example, hierarchical
clustering (Eisen and Brown, 1999) is an agglomerative process in which expression
profiles are joined in function of their distance into a tree. The distances between
members of a tree, clusters or single expression profiles, can be computed in many ways
(Quackenbush, 2001). Because of its simplicity, and graphical display, this method has
become one of the most widely used analysis of gene-expression data. Other preeminent
unsupervised classification techniques are k-means clustering (Tavazoie et al., 1999),
self-organizing maps (SOM) (Kohonen, 1990) and the principle component analysis
(PCA) (Raychaudhuri et al., 2000). Principle Component Analysis is a mathematical
technique to reduce the dimensionality of the data without a significant loss of
information. It reduces the redundant information. This method is sometimes used
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before the k-means clustering and self-organizing maps as it provides an estimate of the
number of clusters. K-means clustering and self-organizing maps use iterative
approaches to find clusters, increasing the distance between clusters while decreasing the
distances of the gene expression profiles within the cluster. With unsupervised
clustering, sometimes the classification of the samples does not correspond to expected
classification. This can happen, for example, when cancer and normal samples are taken
from the same patient. Although there is a difference in the state of the samples, cancer
samples can cluster with their respective patient normal sample, because most of the
background genes stay unaffected by the change of state (normal to tumor).
The supervised methods for analysis present a powerful alternative when sample
stateJtreatment is known. Those methods are very useful for finding gene markers. Each
gene is evaluated for its ability to separate the sample states. Genes that are consistently
differentially regulated between the conditions are very good candidate markers.
Methods to find differentially regulated genes are presented below.
2.3.1 Standard Supervised Analysis Methods
The most straightforward approach is to define a fold change threshold or cut-off that
needs to be exceeded in order to consider a gene differentially expressed. The problem
with this method is that it is arbitrary and does not account for noise in the data. This
method, therefore, generally yields a greater number of false positives.
Affymetnx MAS 5 has its own algorithm for finding differentially regulated
genes. MASS performs three global normalizations: to a set baseline intensity and the
same baseline perturbed by multiplying or dividing by an error factor. Then a Wilcoxon
27
signed rank tests is performed on the probe level data, on for the three different
normalizations (Liu et al., 2002). Finally, a difference call (increase or decrease) is
issued only if the three p-values from the Wilcoxon signed rank tests fall under a user
defined threshold.
Another method frequently used (Roberts et al., 2000) is the Student's t-test for
comparison between two experimental conditions. If the samples come from two
populations that are normal and with equal variance, the t value for testing the difference
between to two population means is computed as follows:
With TC 1 — 5C 2
 being the differences of the means and S',7 _i-2 is the standard error (Zar,
1999). The hypothesis of no differences in the means is rejected when It is above the
thresholds of the t distribution for a specific Type I error rate a (false positive rate) and
degree of freedom. This test assumes that the samples came at random from a normal
population with equal variance. This assumption is often wrong, it has been observed
that some genes behave normally while others do not (Hoffmann et al., 2002). The test is
however quite robust to the normality assumption especially when the number of samples
of the conditions are equal and numerous. Due to the expensive nature of the technology,
many experiments contain few samples and an unequal number of them per condition.
Adapting a parametric test to analysis of microarray data violates the theory on which the
test was based.
Non-parametric tests do not require the estimation of the population variance or
mean and do not state any hypothesis about the nature of their distribution. The most
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commonly used two sample rank test is Mann-Whitney test. The actual measurements
are not used but their rank is. The data is ranked from the highest value to the lowest and
average ranks R1 and R2 are taken for each population of ni and n2 samples. The Mann-
Whitney statistic is calculated as follow:
U is then compared to the table of the critical values of the Mann-Whitney U distribution
at the Type I error rate a and number of samples in each population. Non-parametric
statistics can be used for the analysis of microarray data but require a greater number of
replicates to obtain the same probability of Type II error (false negative) than a
parametric test for the same significant p-values (Zar, 1999). These tests used alone
produce a high rate of false positives due to multiple comparisons performed on the data.
With a type I error a equal to 0.01, one hundred genes out of 10,000 can identified as
significant just by chance. One hundred false positive genes in the result set are too
many and require tedious follow up and confirmatory experiments to be able to find the
true positives.
2.3.2 Correction for Multiple Testing
Multiple comparison procedures are designed to control the familywise error rate, i.e. the
combination of the type I errors from the multiple tests. The most commonly used
technique, the Bonferroni correction consists in dividing a by the number of comparisons
and use this value as the cut-off for the significant p-values (Bonferroni, 1936).
However, this simple correction method has attracted many criticisms (Pemeger, 1998).
The Bonferroni correction is too conservative, each comparison is held to an
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unreasonable standard. In the case of a microarray with 12,000 genes, the p-value cut off
would be 0.001 or 0.05 divided by 12,000, 8* 10 -g and 4 *10 -6 respectively. This might be
an unreasonable high standard and it definitely increases the Type II error were legitimate
results are failed to be detected. Other methods have tried to control the false discovery
rate in a little less stringent manner. The Simes and the Hochberg procedures have been
shown to increase the power of the false discovery rate control compared to the
Bonferroni correction (Benjamini and Hochberg, 1995). For both procedures the p-
valuers are ordered in ascending order and the rejection of the null hypothesis depends in
part on the rank of the p-value. For the Simes procedure a gene is considered
significantly up or down regulated if its p-value is below or equal to its p-value rank
divided by the total number of comparisons and multiplied by the type I error a.
A gene ranked i is significant if:
With Bo) being the p-value of the ordered i t" gene, m the total number of tests performed
on the data and a the type I error rate. Similarly for the Hochberg procedure a gene
ranked i is significant if:
Those methods might still be too stringent when the common number of tests on
micoarray data is between 12,000 and 20,000.
The significance analysis of microarrays method (SAM) (Tusher et al., 2001) has
been described for finding differentially expressed genes. In this method the means and
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standard deviations are used to compute the relative difference in gene expression. This
relative difference d(i) (for a gene i) is very similar to the t value of a student t-test.
Where mA(i) and mB(i) are the mean expressions of the gene i for the state or treatment A
and B respectively, s(i) is the standard deviation and so is a small constant. The small
constant s o helps ensure that the distribution of d(i) is independent of expression,
preventing genes with a very small standard deviation and expression from being
considered differentially expressed. The standard deviation is computed as follow:
Where Ea
 and Ei are the sum over the samples in A and B, c=(1Jn+1Jm)J(n+m-2) with n
and m being the number of samples in A and B. The novelty of this method is that they
use balanced permutations of the dataset to estimate the relative difference of those genes
in a random case. Genes are ranked in descending order of their d(i) value (i.e.: d(1) is
the largest value in the dataset) and the same is done for the permutation d (i) and
averaged. The average of the d(i) is the expected relative difference. By plotting the
relative difference (from the treatment effect) against the expected relative difference we
can observe that for most genes those values are equal. When the difference between
those two measures exceeds a certain threshold A, the genes are considered differentially
expressed. One can substitute one of the balanced comparisons to the treatment
comparison, compare it to the expected relative difference and count how many genes
cross the threshold. By repeating this procedure for all balanced comparisons, one can
obtain an average number of false positives. This method provides the flexibility of an
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asymmetric cut-off for significant genes due to the comparison with random effects. This
method can also be extended to the analysis of 3 or more statesJtreatments using a
Fisher's linear discriminant to obtain the parameter d(i).
2.4 Analysis of Spotted Arrays (two or more samples per arrays)
When analyzing two or more samples per array, one is really looking at the hybridization
of those samples for the different spots (i.e: for example normal vs. malignant). The
amount of oligonucleotides spotted on the chips is in excess of the samples to be probed.
Ratios are inherently independent from the quantities of cDNA or oligo spotted which
can be quite variable from the first slide printed to the last one, or from one slide lot to
another. The question, regardless of the experiment, is still finding genes that are
differentially expressed. Reducing the dataset to the genes that are differentially
expressed helps eliminate noise that could perturb further analysis such as clustering.
Fixed fold change cut-offs of 2 or more can be used but as was observed many times, the
variation in fold-change increases as the signal decreases. A more powerful way to
identify the genes that are differentially expressed within a slide is to calculate a z score
with the mean and standard deviation of the log(ratio). This method defines a global
standard for the chip for fold change difference and confidence. It has the same
inconvenience as the fold change method for it does not take into account the greater
variability of the measurements at lower expression. An altemative approach is to
calculate the z-score in a local manner. Using a sliding window, the mean and standard
deviation of the genes surrounding each data point Ti can be calculated, and the local z-
score can be computed:
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Genes with an absolute local z-score above 1.96 are considered significantly
differentially expressed (95% confidence level) (Quackenbush, 2002).
2.5 Synopsis on Current Status of Microarray Data Analysis
There are many combinations of the methods described above for the analysis of
microarray data from signal estimation, normalization to analysis of significant genes.
The major problem with analysis is that standard statistical tests are ill adapted to the
data. Standard analysis produces too many false positives and when correction for
multiple testing is applied, due to the high number of tests, the corrections tend to be too
conservative. A different approach to analysis is presented in Chapters 3, 4 and 5. In
Chapter 3, a nonparametric method is used to separate cancer samples according to their
selectively expressed genes. This method disregards the normalization techniques that
influence the results by changingJcorrecting signal intensities. In Chapter 4, a noise
boundary model is described, to eliminate spurious fold change, reducing the number of
false positives in further analysis. The issue of using data from different sources to
identify differentially specific cancer biomarkers will be examined in Chapter 5.
CHAPTER 3
ANALYSIS OF THE ROLE OF SELECTIVE
EXPRESSION IN CLASSIFICATION
3.1 Introduction
Application of microarray technology depends on accurate comparison of the level of
gene expression across a set of microarrays. In general, this process requires
normalization or scaling of measurements mere on each microarray, so that differential
changes in gene expression can be observed. In the most frequently used normalization
method, the data are scaled by the ratio of the mean of the frequency distribution of gene
expression levels on one microarray to that on a control microarray. This method works
well as long as the gene expression distributions are linear and have a similar form on all
microarrays. Furthermore, the dependence on the accuracy of this normalization process
is exacerbated by the magnitude of the corrections, which often increase or decrease
measured expression level values by a multiplication factor larger than 6.
This dissertation presents non-parametric methods for microarray data analysis.
This Chapter describes the role of selectively expressed genes for classification as an
altemative method for comparison of gene expression across a set of microarrays that is
not dependent on the standard normalization process. Insteer of using differential gene
expression, the usefulness of selective expression was evaluated. Selectively expressed
genes are generally present in microarrays from one group, and are less likely to be
present in the group that is being distinguished from. This method was tested on data
from the Golub et al (1999) study, whose aim was to classify and predict classes of
leukemia by determining which genes have expression levels that are most correlated
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with different disease states (Golub et al., 1999). Their analysis method was based on the
differential expression levels of all the genes on the microarrays. The expression data
was derived from bone marrow and peripheral blood samples from patients suffering with
acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). These
childhood acute leukemia are blood related cancers arising in the bone marrow. These
cancers are progressing rapidly resulting in the accumulation of immature cells in the
bone marrow and blood. The bone marrow is saturated and can no longer produce
enough normal red blood cells, white blood cells and platelets, leading to anemia, the
lack of immune defense and easy bruising and bleeding. The acute lymphoblastic
leukemia are comprised of two subtypes: B-cell and B-cell leukemia. The original
dataset was split into two sets, a training set and an independent evaluation set. The
training set was used to develop a statistical separation of the two groups, and was
composed only of bone marrow samples. The independent set was then used to evaluate
the separation, but some of the independent set samples were derived from peripheral
blood and therefore erded heterogeneity to the analysis. All of the samples were
hybridized on GeneChips, produced by Affymetnx Inc.
The Affymetnx software MAS 4 employs a decision matrix based on metrics
comparing the intensity of the PM to the MM to determine if a transcript is present (P),
marginal (M) or absent (A). The Golub et al. (1999) study did not take into consideration
the present and absent calls. Using a neighborhood analysis, they were able to classify 36
of the 38 samples in the training set and 29 of the 34 independent samples. They also
used self-organizing maps (Kohonen, 1990) for automatic discovery of the classes. In
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contrast, in this study, present and absent calls were used as indicator of selective
expression, and evaluated for separation of the two types of leukemia.
3.2 Methodology Development
In the initial analysis, the level of gene expression is not used. The samples in the
training set are placed into two groups (27 ALL, 11 AML) and the absent and present
calls of each of the genes in each group are converted into binary numbers, with one
corresponding to present and zero corresponding to absent. Marginal genes and the
present genes with an average difference below zero were also considered to be absent.
The selectivity of each of the genes is computed as the absolute value of the difference
between the real-valued averages of the (expressedJnot expressed) binary values for each
of the two disease groups. With this metric, a gene that is present in all of the samples in
one group and absent in all of the samples in the other group is maximally selective, with
a selectivity of one. In contrast a gene that is absent in both groups, present in both
groups, or present in the same percentage in each of the two groups is not selective at all,
and has a selectivity of zero. A gene would be considered significant if it is twice as
likely to be expressed in one group as in the other. In other words, a gene is considered
significant if it has a selectivity, or absolute difference, that is larger than 0.5. The group
average represents the ideal behavior of a sample from this group and is called an
exemplar. The 7129 genes are sorted into a ranked list from the most selective to the
least selective, and the most selective genes are used to construct an exemplar vector for
each of the two groups. The dimensionality of the exemplar vector is set by the number
of genes that have been included in its definition.
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The likelihood of selective genes occurring by chance was evaluated by randomly
shuffling the data. The samples were randomly assigned to the two groups, which her
the same size as the true AMLJALL groups and the same process was used to construct a
ranked list of selective genes. The average selectivity for each rank on this list was
computed for 45 shuffles of the data, and this is compared with the selectivity of the
genes in the true AMLJALL groups.
The usefulness of selective genes as a method for classifying samples was
evaluated by computing the Euclidian distance from each microarray to each of the two
exemplar vectors. These distances were computed for all of the microarrays in both the
training and independent sets. Members of a group should be closer (smaller distance) to
the exemplar of that group than to the exemplar of the other group. The exemplars
computed from the training set are used to classify the data from the independent set.
A simple form of normalization can be applied to selectively expressed genes.
This normalization seeks to make corrections to errors in the assignment of absent and
present calls, which may have occurred due to variation in the processing of the samples.
In replicate experiments using the same sample on microarrays, some genes with low
expression levels were found that have absent calls on GeneChips with low hybridization
or high background (data not shown). Samples that are more successfully processed
might be more likely to have an increased number of present calls. This hypothesis is
supported by the correlation shown in Figure 3.1. This Figure shows the relationship
between the number of genes with present calls on a microarray and the scaling factor
computed by the Affymetrix software. There is a linear relationship between the inverse
of the scaling factor and the number of genes expressed in the chips (R 2= 0.51).
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Therefore chips with fewer genes expressed require a larger scaling factor, and chips with
more genes expressed have a smaller scaling factor. In general, higher scaling factors
might be needed if the processing of the microarray was less successful. This implies
that microarrays with lower average expression levels might have genes that should be
present, but their expression level is not discemable from the background. This is a
detection threshold problem; the sensitivity of the microarrays changes depending on the
background noise, quality of the RNA and labeling reaction. Refinements of this
technique might leer to greater detection thresholdJintensity cut-off at the frontier
between an absent and a present gene. For normalization, it is impossible to scale up an
absent call into a present call. Instead, microarrays with more genes expressed can be
scaled down by setting the genes with lowest expression level to absent. Provided that the
genes with the lowest expression are the genes masked in the background noise, this
solves the detection threshold problem. This method bases its trust more in the
comparisons of expression levels within an array than across arrays.
Figure 3.1 Linear regression of the number of expressed genes (on the X-axis) to the
inverse of the scaling factor (on the Y-axis).
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More precisely, the expression levels of all of the genes in each microarray are
ranked from the highest expression level to the lowest expression level. The gene with
the lowest ranked expression level on the microarray with the largest number of genes is
set to absent and the selectivity of the genes is computed. This process can be continued
until the selectivity starts to decrease or until all of the chips have at least as many genes
present as the average number of genes present at the start of the process. The selectivity
of a gene increases if it is usually absent in one group, present in the other group, and one
or more of the present calls in the usually absent group are switched to absent because of
low expression values on microarrays with a larger than average number of genes
expressed. For example, a gene that is absent in all of the ALL microarrays except for
one, and is present in the all of the AML microarrays, has a selectivity that is less than
one. If the one ALL present call has a low expression level on a microarray with more
than the average number of present genes, then this normalization will set the ALL
present call to absent, and the selectivity will increase to be exactly one. This method
also reduces the number of genes poorly detected by the technique from the set of genes
used to classify the samples. Some genes might be better detected as present in some
samples and might gain a spurious selectivity index by chance. By changing the call of
those low expressed genes to absent on arrays with a high number of genes found present,
the selectivity of those low expressed genes will be decreased compared to the selectivity
of genes with higher expression values.
In the initial analysis of the training data, the number of present calls ranges from
1352 to 2877. The normalization is applied in the first instance keeping the highest
ranked 2500 expression levels from each of the microarrays. Any of the microarrays that
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has more than 2500 genes present has the genes with the lowest expression levels now
forced to be absent. The genes with selectivity greater than 0.5 prior to this process are
called the selective genes. The difference between the number of selective genes that
increase their selectivity and the number of selective genes that decrease their selectivity
is computed. The same process is repeated in which the highest ranked 2250, 2000,
1750, 1500, and 1352 genes are kept as present, and find the number of genes that
optimizes the selectivity of the selective genes.
3.3 Results
It can be observed in Figure 3.2 that a substantial fraction of the genes are absent and this
suggests that selective expression might usefully distinguish between groups of samples.
If the majority of the genes are always present then the data must be normalized to look
for differential expression. Also, there is a large variation in the number of genes present
from one slide to another, from 1352 genes found present in sample 27 to 2890 in sample
5, with an average of approximately 2000 out of over 7000 genes.
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When the selectivity metric described above, is applied to the two leukemia
groups, 121 genes are found to be selective. This included several genes that were also
found to be important in the distinction between the two types of leukemia by Golub et
al. (1999); MB-I required for the B-cell antigen receptor (Payelle-Brogard et al., 1999),
zyxin, HOXA9 involved in myeloid differentiation (Casas et al., 2003; Zeisig et al.,
2004), and cyclin D3 involved in cell cycle and proliferation (Table 3.1). In the list of the
24 most selective genes we see that some genes, such as the myosin light chain, are more
expressed in the ALL leukemia. Others, such as zyxin, are expressed more often in the
AML group. As described in the methods section, this selectivity was compared to 45
random shuffling of the samples into the two groups. Those selective genes had
significantly higher difference in expression than the randomly shuffled sets (last column
on the table). Figure 3.3 shows the selectivity of the genes, after normalization. The x-
axis is the position of the gene in this ranked list, and the y-axis is the selectivity.
Figure 3.3 The selectivity level is the absolute difference between the ALL exemplar
and the AML exemplar ■ . The selectivity level between the shuffled samples q is
represented as a comparison.
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Table 3.1 Most Selectively Genes Expressed in the AMIJALL Training Set
The average expression for the ALUAML groups and the absolute difference, are
displayed as well as the absolute difference of the shuffled set with the standard deviation
and the number of standard deviation away from the AML-ALL real grouping.
In order to classify the samples in one group or the other, the Euclidian distance
of their binary call (1 for present and 0 for absent) to the exemplar was computed. This
distance among the 10, 20, 30 most selective genes, was then averaged and the closest
exemplar was determined. With the ten most selective genes, the 2 groups in the training
set were completely separated (Figure 3.4).
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After applying the normalization process described above, the selectivity was
maximized by retaining, as present, the 2000 genes on each microarray that have the
highest expression level on that microarray. The lower two panels of Figure 3.4 show
that this normalization improves the separation of the two groups. Using the ten most
selective genes, the AML samples are closer to the AML exemplar and that the ALL
samples are further from the AML exemplar.
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Figure 3.5 shows the effect of changing the dimensionality of the exemplar vector
on cluster separation. The prior analysis was based on the ten most selective genes, or
equivalently on ten dimensional exemplar vectors. The x-axis of this Figure is the
dimensionality of the exemplar vector. Again the included genes have been ranked, and
the genes are erded to the exemplar in rank order from the most selective to the least
selective. The y-axis is the distance of each of the samples from the ALL exemplar.
Each sample is plotted as a distinct line. The top panel shows the distances prior to
applying the normalization process and the lower panel shows the distances after
applying the normalization process. Over most of the range shown in the Figure the
normalization process has increased the separation of the two groups. As more genes are
included in the exemplar vector the graphs gradually move closer together.
The same analysis was applied to the independent set, but the distances were
computed to the exemplar that was computed from the training data. As shown in Figure
3.6, this technique was successful at separating the two groups. Only one sample,
number 66, was incorrectly classified. The top panel shows the distances of the two
groups from the ALL exemplar prior to normalization, and the lower panel shows the
distances after the same normalization process her been applied to the independent
evaluation set. In this normalization no additional optimization was performed, and as
before the 2000 genes with highest expression level from each microarray were kept as
present. Note that again the normalization increases the separation of the two groups.
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Figure 3.5 ALL samples q and AML samples MI , (A) Distance of the training set
samples to the ALL exemplar before normalization. (B) Distance of the training set
samples to the ALL exemplar after normalization.
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Figure 3.6 ALL samples q and AML samples ■ , +++ misclassified sample number
66, (A) Distance of the independent set samples to the ALL exemplar before
normalization. (B) Distance of the independent set samples to the ALL exemplar after
normalization.
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The same method was used to examine other possible classifications of the data.
There was information in the data about the sub grouping of the ALL samples into T-cell
and B-cell type leukemia. Just as was found in the ALL-AML classification, genes were
identified in the T-cell to B-cell groups that are more selective than expected by chance,
as evaluated by shuffling the samples. The resulting exemplar vectors were able to
completely separate the T-cell and B-cell groups in the training set without error. In the
independent set, one out of the 20 ALL independent samples, number 67, which was a
peripheral blood sample, was misclassified. The method was also applied to the
classification of success and failure of treatment and to female and male subjects. In both
of these two cases there was no significant difference between the selectivity of genes
found in the real groups from that found in the randomized groups. The absence of a
correlation in the treatment response case may be due in part to the small number of
samples (11 in the training set).
3.4 Conclusion
Selective gene expression is sufficient for separating the AML vs. ALL samples, and T-
cell vs. B-cell samples. Selective expression does not have the same dependency as
differential expression on normalization of microarray data, and for this reason it may be
more robust regardless of variations in processing. Some of the most selective genes
were differentially expressed in the Golub et al. (1999) study (e.g. MB-1, zyxin, HOXA9,
cyclin D3). Other genes like Catalase (X04085) which were differentially expressed in
both ALL and AML, but not selectively expressed were not selected by this method.
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However, TCL1 was not found to be differentially expressed in the prior study, and was
found to be selectively expressed with this method.
The shuffling method provided a useful verification of the use of selective genes
to classify the data into groups. The AML and ALL groups, and the T-cell the B-cell
groups were far from the randomly constructed datasets, while the success—failure
classification and female—male classification was close to chance.
This approach is orthogonal to prior studies and complementary, since it focuses
on genes that are selectively expressed rather than on differential expression levels. This
simple approach is very robust, powerful and easy to use in diagnostic microarray
development as it contains strongly expressed genes. A synthesis of the qualitative and
quantitative methods should improve the classification performance, and add
understanding to the mechanism of action of the genes involved in some pathology.
This work demonstrated the possibility of circumventing the normalization
problems by using only selectively expressed genes. However, it then raises the issue of
definition of the expression versus no expression. There is no real cut-off and finding
expression depends on the background noise and sensitivity of the technique. There is
also quantitative information overlooked with this method. In the next Chapter a noise
boundary model is presented. This model is designed to enable the analyses of
differential gene expression.
CHAPTER 4
ASSESSING THE NOISE LEVEL AND TRUST THRESHOLD FOR
DIFFERENTIAL EXPRESSION ON AFFYMETRIX GENECHIPS.
4.1 Introduction
In this Chapter the characteristics of the noise of the GeneChip microarray data is
evaluated. When noise is consistent and reproducible it can be filtered from the data, and
some false positives can be eliminated. There are two major sources of noise in
microarray data. The first source of noise is biological which comprises variations
between different patients, tumor location, variation of cellular composition among
tumors, heterogeneity of the genetic material within tumor due to genomic instability, and
differences in sample preparation. Biological noise cannot be corrected but it can be
accounted for with statistics using replicates of the treatment conditions. The second
source of noise is the microarray technical noise that comprises nonspecific cross
hybridization, efficiency of the labeling reaction and differences between microarrays.
The noise derived from experimental technique is reproducible and the boundary of the
noise can be modeled. It has been observed, that in differential comparisons of any given
gene, there is a greater variance in the fold-change calculation at lower signal intensities
(Mutch et al., 2002; Tu et al., 2002). When comparing replicate samples, lower
expression values tend to have the greatest variance in signal intensity. This suggests that
larger errors can occur when lower signals are used to compute fold-changes in
differential comparisons. Fold change, computed in this way, can leer to extraneous
inclusions in lists of significantly up-regulated or down regulated genes. For example, a
fold change of two calculated from intensities of 25 and 50 may not be as trustworthy as
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a fold-change of two determined between intensity values of 2,000 and 4,000. Thus, the
purpose of error boundary modeling is to reduce the influence of less trustworthy fold-
change calculations in the differential analysis of microarray data. The technique of
coupling a noise boundary model to an analysis method has previously been shown to be
useful for two color cDNA arrays (Baggerly et al., 2001; Hughes et al., 2000; Ideker et
al., 2002; Yang et al., 2002a).
4.2 Development of a Noise Boundary Model
It would be ideal to construct the noise model to measure the technological noise with
replicated data, but this type of data is not always available. One can use replicates for
the same condition: i.e. different normal biopsies of tissues from different patients. In
this case the noise model not only measures the technique error but also some of the
biological variability. This could be useful in the sense that it accounts for tissue
variability in the design of the error model. This approach is in a way similar to the work
done by Mutch et al., 2002. Their analysis relied on 2 assumptions: 1) the signal is more
variable closer to the low intensity detection threshold, 2) empirically, from the literature,
regardless of the method of gene selection, only a few percent of genes change due to
treatment (less than 5%). Based on these assumptions, they have created a limit fold
change model by making a histogram of absolute fold changes as a function of minimum
intensity. Absolute fold changes were binned in the size of 200. Only the top 5% probe
sets of each bin were selected to be considered differentially regulated. Their data
contained no biological replicates, insteer they pooled samples, and they her only one
technical replicate. Their method of selecting the up-regulated or down-regulated genes
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consisted in taking the top 5% of the absolute fold changes in a uniform manner across
the intensity range. In contrast, the error boundary model was created to eliminate
untrustworthy fold changes from the analysis. This boundary was designed to be used as
a preprocessing step before evaluation of the data. In Chapter 5, publicly available data
(Bhattacharjee et al., 2001; Su et al., 2001; Toruner et al., 2004; Welsh et al., 2001a;
Welsh et al., 2001b) is going to be used to find cancer markers. This Chapter is going to
describe how the noise boundary model was designed for those data sets. First, two
questions were asked: which probe-set intensity measurement method should be used,
and can a noise boundary model be designed for each method? It was noticed that for
each method, MASS, dChip PM-only and RMA, for any combination of normal biopsies,
there was an increase of the fold changes for a decrease in the average intensity of the
probe-set. Figure 4.1 displays a scatter plot of the fold-change plotted against the average
intensity for each probe set from arrays from two normal lung tissues using MASS for
signal estimation. This plot, commonly named a volcano plot due to its shape, shows a
considerable increase in signal variation at smaller signal amplitudes. The initial
broerening in fold change starts at a signal intensity of 200 with 61.6% of the genes
having an average signal intensity lower than this value. Significant broerening occurs
for signal values with less than an average signal amplitude of 100, which corresponds to
over 44.8% of the measurements of a chip scaled at 300.
To model the noise, a fold-change threshold boundary was drawn for each
comparison between normal biopsies for each cancer studied. This was accomplished by
binning the data into fixed width bins. Each bin was set to include 200 expression values.
A percentile of the fold-change was calculated for each bin, and considered to be the
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error boundary. Figure 4.2 shows the 80 th percentile error boundary values for each of
the bins of the replicate data displayed in Figure 4.1.
Figure 4.2 The 80 th percentile of the absolute fold change (y-axis), from two lung
normal samples, is plotted against the average signal (x-axis) for each bin of 200 genes.
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For modeling purposes, the percentile was plotted against the inverse of the
average bin revealing a linear relationship that can be characterized with a slope and
intercept. This linear relationship was seen with all the probe-set signal estimation
methods (MASS, dChip PM-only and RMA). In Figure 4.3, this linear relationship can
be seen for the same two lung samples as Figure 4.2. The linearity stops for an average
bin intensity of 25 (1J0.04) at which point the gene expression may not be reliable
because it is too close to the detection limit of the technology. Because of this, a
minimum intensity cutoff is going to be set to preserve the linearity. This minimum
intensity cutoff is another parameter, after the percentile, which is going to greatly
influence the model. The next section will present a sensitivity analysis on these two
parameters; expression cut off and percentiles.
Figure 4.3 The 80 th percentile of the absolute fold change (y-axis), from two lung
normal samples, is plotted against the inverse of the average bin signal intensity (x-axis).
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4.3 Sensitivity Analysis of the Parameters (cut off and percentile)
and the Probe Set Intensity EDtraction Methods
To be able to perform a sensitivity analysis on the parameters, a standard dataset was
chosen. The Latin square replicate data set (Hubbell et al., 2002) was used for this
purpose as it contains genes replicated for their expression levels and spiked in genes
with different concentrations on different chips. Since the concentration of these genes
was the only difference between the arrays, the true and false positive rates could be
accurately determined. The 16 samples of the replicate set in the Latin square dataset
were considered replicates for modeling the noise as the number of probe-sets spiked in
represents only a small portion, less than 0.0012%, of the total number of probe-sets. For
this replicate set, a sensitivity analysis was performed around two parameters: percentile
taken for each bin for regression and minimum intensity cutoff. This sensitivity analysis
was also performed for the different methods of probe set intensity extraction: dChip PM
only, MAS 5 and RMA. The sensitivity analysis consists in observing the variation of
the slope and intercept obtained from the linear regression on the boundary defined by the
percentile and cut-off. The average slopes and intercepts were then graphed as a function
of those two parameters.
For dChip PM only and RMA, the parameter that influences most the average
slope is the minimum intensity cutoff (Figure 4.4 and 4.5). Only the highest percentiles,
above 94, have an effect on the slope and decrease it drastically due to the introduction of
noisy data. On the other hand, the slopes increase steerily with the minimum intensity
cutoff for RMA and with a delay for dChip PM only. This can be due to non linear
increase of the absolute fold change with the decrease in bin intensity. The increase has
concave shape just like in Figure 4.2, the more the low end data is cut, the higher the
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slope of the regression. Also as an artifact of the transformation of the x-axis, inverse of
the average bin intensity, there is also a non-equidistant repartition of the bin percentile
fold change. This result in bin with a low average intensity having more weight on the
regression than the bins with higher intensities: i.e. more bins are regrouped in the 0 to
0.02 range than 0.02 and 0.04 range. As the average intensity gets higher, the differences
of the fold change percentiles decrease and the inverse of the average intensity decreases
further. Eliminating the low intensity bins has a greater effect on the slope. Also, slopes
with a cut-off higher than 500 are probably not reliable as the regressions were performed
on less than 20% of the original data.
Figure 4.4 Three dimensional graph of the effect of the minimum intensity cutoff and
percentile on the slope of the regressed percentile to the average intensity of the bins,
with data obtained with the RMA (Ihaka and Gentleman, 1996).
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Figure 4.5 Three dimensional graph of the effect of the minimum intensity cutoff and
percentile on the slope of the regressed percentile to the average intensity of the bins,
with data obtained with the dChip PM only.
In Figure 4.6, MAS 5 average derived slopes are both influenced by the minimum
intensity cutoff and the percentile. The slope increases in a step like manner increasing
with a larger percentile and a larger minimum intensity cutoff. The magnitude of the
slope is also very different between MAS 5, dChip PM only and RMA. For the 80 th
percentile and a minimum intensity cutoff of 100, the average slope is 157.6 for MAS 5,
7.7 for dChip PM only and 2.15 for RMA. Since the regression is performed on the
inverse of the average intensity, the slope gives an indication of the noise in the low
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intensity range. Because the Latin square GeneChips can be considered as replicates, it
can be inferred that RMA and dChip PM only are better controlling the noise in the low
intensity range compared to MAS 5. One explanation could be the fact that dChip PM
only and RMA attenuates the signal compared to MASS, reducing both noise and true
fold change (unpublished data, appendix A). In all three cases there are conditions where
the slope is stable for minor variations of the cutoff or percentile.
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For all three methods of probe-set intensity extraction, the average intercept is
insensitive to the percentile and the minimum value cutoff except for the extreme values
of those parameters: i.e. 98 percentile and no minimum value cutoff (see Figures 4.7, 4.8,
4.9). For the 80 th
 percentile and a minimum intensity cutoff of 100, the average intercept
is also very similar between the methods: 1.08 for MAS 5, 1.13 for dChip PM only and
1.12 for RMA.
Figure 4.7 Three dimensional graph of the effect of the minimum intensity cutoff and
percentile on the intercept of the regressed percentile to the average intensity of the bins,
with data obtained using RMA (Ihaka and Gentleman, 1996).
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Figure 4.8 Three dimensional graph of the effect of the minimum intensity cutoff and
percentile on the intercept of the regressed percentile to the average intensity of the bins,
with data obtained using dChip PM only.
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Figure 4.9 Three dimensional graph of the effect of the minimum intensity cutoff and
percentile on the intercept of the regressed percentile to the average intensity of the bins,
with data obtained using MASS (Affymetrix).
To evaluate the performance of the noise boundary model to identify the two fold
change spiked-in genes in the results and eliminate false positives from the results, the
sum of the rank of 12 out of the 14 spiked probes was evaluated. Two out of the 14
spiked genes were omitted because either their concentration was too low to be detectable
(1597_at was spiked at the concentration of 0 to 0.25 pm) or the amount had saturated
(1708_at was spiked at 256 and 512 pm). The noise boundary model was applied to any
combination of the chips spiked at one concentration to all the other chips spiked at the
other concentration. For every gene, up-regulation or down-regulation was then recorded
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as the fold change was compared to the noise boundary. The maximum number of fold
change directions was then divided by the number of comparisons. This resulted in an
index called the Event ratio (Er) which is discussed in more detail in Chapter 5. Those
probe-sets were ranked in descending order according to their Er score (Highest Er score
is assigned the number 12626: i.e. the number of genes in the chip). The scores obtained
were summed for the 12 spiked probe-sets and the results were normalized. The perfect
score is 1. The result with the probe signal estimated with MAS 5 is presented in Figure
4.10. A plateau can be observed at 0.99 for most of the range for percentile and cutoff
values. However there is a sharp decrease for a low cutoff, i.e. zero. The percentile also
her little effect until a percentile higher than 94% was reached. The high percentile and
low cutoff introduce more noise in the data setting the noise boundary model too high,
therefore reducing the Er score of the spiked-in genes. The graph (Figure 4.11) for the
signal estimation with RMA is similar to the MAS 5 in that most of the area covered by
the simulation for the percentile and cutoff is a plateau at 0.99 for the sum of rank of the
spiked in genes. In the same manner, the sum of ranks decreases for higher percentiles
(above 96%). However, in this case, the rank is insensitive to low intensity cutoffs but
decreases with higher cutoffs, with a first dip with gene intensities lower than 1600, and a
second for intensities of 2100. The higher cutoffs are actually cutting most of the data to
construct the model. For perspective, the chips are scaled to an average intensity of 300.
The dChip PM only algorithm did not seem to perform as well as MAS 5 and
RMA, as its plateau was smaller and more sensitive to the parameters (Figure 4.12). The
plateau average is also 0.99, but it is limited to percentiles lower than 90% and a
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minimum intensity cutoff lower than 1100. Overall, MAS 5 seemed to be more robust, as
the noise boundary model performance gradually decreased with the percentile.
Figure 4.10 Three dimensional graph of the effect of the minimum intensity cutoff and
percentile on the score of the spiked in genes of the replicate set of the Latin square
dataset, with data obtained using MASS (Affymetrix).
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Figure 4.11 Three dimensional graph of the effect of the minimum intensity cutoff and
percentile on the score of the spiked in genes of the replicate set of the Latin square
dataset, with data obtained using RMA (Ihaka and Gentleman, 1996).
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A compromise has to be made between setting a noise boundary model to low,
finding all the spiked genes with a lot of false positives and setting the noise model too
high. At this point the model is so conservative that only a few spiked in genes are
found. Figure 4.13 displays the false positive rate when an Er cutoff is set to 0.9,
equivalent to a gene being consistently over or under expressed in 90% of the
comparisons. The false positive rate is very high for a percentile of 0.98. This artifact is
due to the presence of only one gene which is a false positive in the result set. The false
positive rate decreases sharply with the percentiles and then increases again as the
boundary model becomes less conservative.
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4.4 Sensitivity Analysis Discussion
Noise modeling can be performed for all of the methods. MAS 5 was shown to be noisier
for low intensities but the correction using the noise model seemed to perform very well
as its performance decreased gracefully for finding spiked genes. MAS 5 will be used in
further studies because of its wide use for signal intensity estimation and its robustness
for the two parameters tested. A cutoff for the minimum intensity of 100 and the 80 th
percentile was selected for the model parameters as they are in regions where the slope,
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intercept and rank are not very sensitive to change, and where the false positive rate is
reasonable.
4.5 Evaluation of the Noise Model on Real Data
Figure 4.14 displays the 80 th percentile error boundaries for five different normal tissues
as a function of the inverse average bin intensity. Bins with an average intensity lower
than 100 (above 0.01 in the Figure) were not displayed. They are below the minimum
intensity cutoff and hinder the linearity relation of the percentile to bin intensity. A
leveling off of the fold changes at high was also noticed; this leveling is due to saturation
on the chip. To decrease the effect of the saturation on the regression, the top 8% of the
genes were eliminated i.e. top 5 bins with lowest inverse average intensity. The slope
and intercept were then calculated for each cancer dataset as they give an indication of
the noise level at low and high expression values respectively. For each comparison of
normal samples in a tissue, the slope and intercept were averaged (Table 4.1). There
seems to be a negative correlation between the slopes and intercepts. The higher the
intercept the lower the slope. If a dataset contains an inherent high background, the
signal to noise ratio is decreased. The intercept will increase as the 80 th percentile is
going to be higher. The slope on the other hand is not going to increase, and might even
decrease as the low intensity background noise remains constant. Before using this noise
boundary model in Chapter 5 to find cancer markers, the stability of the slope and
intercept for the different datasets must be evaluated. One of the differences with the
Latin square replicate data set is that these public data consist of biological replicates of
normal tissue insteer of technical replicates. The cancer biopsies were not used in
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designing the noise model as they might be more variable than normal tissue. The first
two simulations were then performed for all normal tissue samples to confirm that the
minimum intensity cutoff and percentile selected were also in regions where their slope
was also insensitive to small changes (Figures 4.15, 4.16, 4.17, 4.18, 4.19). Figures for
the simulation of the effect of the cut-off value and percentile on the intercepts are
presented in Appendix B. For all the normal tissue, the results from the simulation are
very similar.
67
Table 4.1 Average Slopes and Intercepts for the Different Tissue Types
This table displays the average slope and intercept of the regression of the 80 th percentile
of the bins by the inverse of the average expression per bin. The bin size was 200 and the
minimum intensity cutoff was 100.
Figure 4.15 Three-dimensional graph of the effect of the minimum intensity cutoff and
percentile selected on the slope of the regressed percentile to the average intensity of the
bins for the prostate normal biopsies.
Figure 4.17 Three-dimensional graph of the effect of the minimum intensity cutoff and
percentile selected on the slope of the regressed percentile to the average intensity of the
bins for the ovarian normal biopsies.
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Figure 4.19 Three-dimensional graph of the effect of the minimum intensity cutoff and
percentile selected on the slope of the regressed percentile to the average intensity of the
bins for the oral normal biopsies.
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4.6 Conclusion
There is a characteristic increase in the range of fold change values that occur at lower
expression levels on Affymetrix GeneChips replicate arrays. This occurs with all
techniques for estimating gene expression levels from GeneChips measurements. This
increase in fold change was found to be consistent and could be characterized through
regression analysis in the three different, commonly used, probe set intensities extraction
methods (MASS, dChip PM only and RMA). This noise was also shown to be consistent
not only on replicate arrays but also on normal tissue replicate data. The boundary of this
noise can be modeled for all data extraction methods and is found to fit well with an
inverse linear function. From this observation, a noise boundary model was derived.
This noise boundary is used in the next Chapter to determine if a fold change is above the
noise level and relevant to the analysis, eliminating spurious false positives. It is
essential to eliminate the background level fold changes since the multiplicity of the tests
introduces hundreds of false positives. This model increases the trust and confidence for
identifying differentially expressed gene markers. Another ervantage of the noise
boundary is that it is tailored to the noise level in the different normal tissues. This
Chapter presented an original analysis of the noise. Using this noise boundary as a
preprocessing step to an analysis method will help reduce the number of false positives
obtained. Chapter 5 will apply this noise boundary model to a non-parametric analysis of
microarray data from different research laboratories to delineate cancer markers.
CHAPTER 5
NONPARAMETIC DIRECTIONAL CHANGE ASSESMENT ALGORITHM
IDENTIFIES TISSUE SPECIFIC MARKERS FOR DIFFERENT
CANCER TYPES
5.1 Hypothesis
To be able to find markers, data from different research groups might be needed as each
group has expertise on their cancer studied and access to samples. One particular concem
when using microarray data derived from different labs is that chip-to-chip normalization
cannot eliminate differences in scanner settings, image processing software, labeling, and
hybridization protocols. The laser power on the scanner can be different from one scanner to
another causing saturation of some spots. The quality of the RNA isolated can influence the
mRNA species present and also the success of the labeling reaction in ways that are not well
known, difficult to control and impossible to account for. A few studies (Ramaswamy et al.,
2001; Su et al., 2001) successfully classified different cancers by their molecular profile on
microarrays using hierarchical clustering and support vector machine (SVM) techniques
(Brown et al., 2000). Both studies found that their markers comported a high number of
genes that distinguished the normal tissues of origin.
The approach taken in this Chapter is rerically different from previous efforts. Here,
cancer samples are compared first to corresponding normal tissue, eliminating the tissue
effect genes. Then the most discriminating genes for each cancer vs. normal cells are
compared among cancers. The starting hypothesis is that the most reliable discriminating
markers are transcripts that are differentially regulated in a consistent manner between
normal and cancer biopsies. Also the normalization problems due to lab specific parameters
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(scanner settings, labeling) and even tissue specific artifacts are avoided, as each cancer
biopsy is compared to its corresponding normal tissue processed by the same research group,
in the same environment. These environmental parameters and artifacts are assumed to be
the same for the normal and cancer biopsies and should cancel out when compared. This
allows the selection of genes that best separate normal biopsies from tumors. These
classifiers were then evaluated to see if they are specific to the different types of cancers.
Since gene expression measurements of individual Affymetrix GeneChips probe sets do not
always follow a normal distribution, a non-parametric method was used.
The method to find discriminating markers uses an unweighted voting scheme. This non-
parametric method for marker selection was chosen to avoid making any assumptions on the
shape of the data distribution. However, one drawback is that errors in microarray
expression measurements cannot be accounted for as they vary in scale across the dynamic
range of the technique's sensitivity. To remedy this problem, the noise boundary model
described in Chapter 4 was used. The computed boundary for the noise makes the selection
criteria more stringent, eliminating many false positives signals, and highlighting genes that
are consistently differentially expressed in comparisons between a cancer and its
corresponding normal tissue. This integrative approach can highlight sets of distinct
transcripts distinguishing a variety of solid tumors.
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5.2 Materials and Methods
All of the microarray data used in this analysis was derived from RNA isolated from biopsies
and hybridized on Affymetrix GeneChips HG-U95A, HG-U95Av2 or HG-U133A. All the
research groups used the same standard procedure for labeling the cRNA, hybridization and
scanning (Wodicka et al., 1997). The datasets were obtained from several different sources:
Data from 24 breast cancer biopsies were from Su et al.(Su et al., 2001), and the three
corresponding normal breast tissue biopsies were provided by Garret Hampton from the
Genomics Institute of the Novartis Research Foundation. For prostate cancer, the dataset
was derived from 21 tumors and 8 normal biopsies (Welsh et al., 2001a) whereas the ovarian
cancer dataset originated from 14 tumor and four normal biopsies (Welsh et al., 2001b).
Finally, the lung cancer dataset consisted of biopsies from 61 samples of lung
adenocarcinoma, 20 lung carcinoids, six small cell lung cancer, 21 squamous lung cancers,
and 17 normal lung tissues (Bhattacharjee et al., 2001). Out of the 61 adenocarcinoma
samples, 19 were replicates and 52 were sub-divided into five categories according to
Bhattacharjee et al.( 2001) (Bhattacharjee et al., 2001): seven in cluster 1, nine in cluster 2,
15 in cluster 3, 13 in cluster 4, and eight samples of colon metastasis. The oral cancer dataset
consisted of 4 normal and 16 oral cancer biopsies (Toruner et al., 2004). The directional
change assessment and the noise model algorithms were programmed using Python, and the
comparison for markers was performed with Excel. Latest annotations and Gene Ontology
classification were downloered from the NetAffx" M Analysis Center3.
http:JJwww.affymetrix.comJanalysisJindex.affx March 2004
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5.3 Nonparametric Microarray Data Analysis
Several methods have been described for combining data from microarray experiments
where there are replicates for both experimental and control conditions. Often, the numbers
of replicates are small and the distribution is not normal. For the same difference in mean,
depending on the distribution of the data, the overlap of two distributions can be dramatically
different. Our ideal markers would be genes with no overlap in their distribution; the
consistency of change is therefore more interesting than the amplitude. There is still a
problem due to the low number of replicates, the multiple testing of 12,000 genes and the
inherently noisy measurement. For this reason, the noise boundary model was incorporated
with the non-parametric data mining. The noise boundary helps eliminate some of the noise
that is proportional to the probe intensity measured and helps eliminate false positives due to
chance, because we are performing multiple testing on more than 12,000 genes with random
noise. The combination of the non-parametric voting scheme to find consistently
differentially regulated genes with the noise model will be referred as the directional change
assessment algorithm in the rest of this Chapter. For each transcript, the ratio of expression
intensities (fold change) of each cancer biopsy to all normals was determined. If the absolute
value of the ratio is above the noise boundary, up-regulation (+) or down regulation (-) is
recorded. If the ratio is below the value given by the noise boundary for the average of the
intensities, then the fold-change is considered insignificant and a no-change (0) direction is
assigned. The Event ratio (Er) is described by:
The closer the Er is to 1, the more consistent the direction of change is for that gene.
Conversely, if the Er score is close to 0.5, then the gene is inconsistent with regard to its
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directionality, considered noisy and thus cannot be used as a reliable marker for disease
classification. To test the validity of this approach, the samples were shuffled 100 times
between the categories (cancer and normal) and Er computation was repeated. Each time the
data was shuffled, the probe sets were sorted by descending Er scores and the probe set
information was discarded and replaced by its rank. The average and standard deviation of
the ranks was then computed and compared to the results obtained for the cancer versus
normal biopsies. For all the comparisons performed, higher Er scores were obtained in the
case of a cancer versus normal classification than with randomly shuffled sets. These results
confirm that the genes found significant with a high Er score are not just random in this case.
An illustration of the results obtained with the breast cancer versus normal biopsies can be
seen in Figure 5.1, the Figures for the other cancers are in Appendix C.
Figure 5.1 Comparison of the Er score of the 500 top ranked probe sets for breast cancer
versus normal breast biopsies. Er score for the real breast cancer vs. normal biopsies  — ,
Average Er score of the 500 top ranked probe sets of the 100 shuffling sets — , one standard
deviation away form the average shuffled sets .
5.4 Testing the Er Algorithm
To compare the Er algorithm with the noise model to other commonly used analysis
methods, the replicate set from the Latin square dataset was used. In this dataset, fourteen
probe sets were spiked in at a two fold level. The T-test performed on this data found 175
probe sets with a p-value below 0.01, including the fourteen spiked genes. Although this
method collected all the spiked genes, it also highlighted 161 false positives. The percentage
of true to false positives is only 8.6%. There is a multi-testing problem, with 12,000 tests
times the type I error rate: 0.01, 120 probe sets are expected to have a p-value below 0.01.
To correct for the multiple testing, one common method is the Bonferroni (Benjamini and
Hochberg, 1995; Bonferroni, 1936; Perneger, 1998) method which found seven genes to be
significant with six true positives. The methods of Hochberg and Simes (Benjamini and
Hochberg, 1995), both found 16 significant genes with 11 true positive. The SAM (Tusher et
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al., 2001) method also corrects for multiple testing, found 21 genes significant including 12
true positive with a delta of 1.54. Although they were able to find 85% of the spiked genes,
their false positive rate was underestimated; they estimated a median false positive rate of
4.58% when it was 42% insteer. The Er model described above with a cut-off of 0.9 found
12 genes with 8 of them being true positives. Without the noise model, 93 were found with
an Er score above 0.9. The Er model with the noise boundary model is well within the
separation levels of the standard techniques for eliminating spurious false positives. It would
be interesting to compare these methods on multiple datasets as the results and performance
of the different techniques may be dataset dependant. In the Latin square dataset, the spiked
genes are independent, but in a real scenario the genes may not be independent and the result
of one test may depend on the levels and test results of other genes. It is not known how
much this affects the standard multiple test corrections. Also the Latin square data set is a
very clean dataset with very little noise and few differences in scaling between chips
(Affymetrix, 2002b). Under real world situations, data may be noisier and this may affect the
performance of the different methods. It is worth noticing, that the fold change that the probe
sets were spiked at was two fold, but the actual read intensity only shows an average of 1.53
fold. These methods decrease the number of false positives compared to the t-test alone but
some true positive are occasionally missed. This is partly due to the fact that the spiked
genes were erded at a range of concentration testing the limit of detection from very low to
high signal saturation.
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5.5 Differentially Expressed Genes
The Er model was then used to compare each cancer biopsy to its corresponding normal
tissue. In the absence of error modeling, the directional change algorithm identified 1,910
probe-sets that had an Er score above 0.9 in ovarian cancer, 1,355 in breast cancer, 1,730 in
oral cancer and 322 in prostate cancer. In contrast, incorporation of error modeling
dramatically reduced the number of probe-sets with Er scores above 0.9 to 272 for ovarian,
177 for breast, 129 for oral cancer and 2 for prostate cancer. For lung cancer biopsies, the
distinct sub-classes were compared against normal tissues and 15 probe-sets with an Er value
above 0.9 in all comparisons were uncovered. The following sections will present the results
of the algorithm for the different tissues. Some gene markers found are alreery known
markers and or have a biological function that might take part in the oncogenic process.
These markers are reviewed below. Other gene markers may sometimes not seem relevant to
the condition. These might be genes co-regulated or downstream from a pathway affected in
cancer, and they can be very useful for diagnostic and classification. There are many ways to
regulate proteins concentration in a cell and it might not always be seen at the RNA level, but
its effect can be seen on the RNA levels of the downstream genes expression. Although not
reviewed here, these genes are very useful for diagnostic and classification.
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5.5.1 Breast Cancer
The breast cancer dataset is composed of 21 infiltrating ductal carcinoma and 2 normal
biopsy samples, with 2 technical replicates. One hundred and seventy seven probe sets were
found to be differentially regulated between the normal and cancer samples with Er scores
above 0.9, most of them being down regulated (151 out of 171). Thirty two of those probe
sets encoded for different ribosomal proteins, all down-regulated, averaging 2-3 fold down
compared to the normal samples. These genes are located on 19 different chromosomes so a
deletion would not be able to explain this down regulation. Methylation of ribosomal DNA
has been reported in human breast cancer (Yan et al., 2000) and could be the cause of the
decrease in mRNA encoding ribosomal proteins. Other notable genes involved were:
thrombospondin 2 (THBS2), a known marker (Clezardin et al., 1999) involved in
angiogenesis (de Fraipont et al., 2001) was up regulated, and caveolin 1 (CAV1) was down
regulated. Caveolin-1 acts as a tumor suppressor protein. When expressed at high levels, it
inhibits cell proliferation (Fiucci et al., 2002).
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5.5.2 Ovarian Cancer
The ovarian dataset is derived from four normal and 14 tumor biopsies (serous papillary
ovarian carcinoma) (Welsh et al., 2001b). Two hundred and seventy two probe-sets were
identified in the ovarian dataset with an Er score above 0.9, of which the top 30 are presented
in table 5-2. Notably, genes are involved in cell-to-cell adhesion and are epithelial cells
markers, such as the secreted phosphoprotein 1 (SPPI), claudin 3, 4 and 7 (CLDN 3, 4, 7),
keratin 7, 8 and 18 (KRT 7,8,18), agrin, and cahedrin 1 and 6 (CDH 1, 6), were up regulated
by at least 3-fold in ovarian cancer samples. As was previously suggested (Adib et al., 2004)
this might suggest an epithelial origin of the tumors. Eighty to ninety percent of the ovarian
cancers arise from the epithelia (Auersperg et al., 1999). Genes involved in the regulation of
cell growth; v-fos (FOS), quiescin Q6 (QSCN6), protease serine 11 (PRSS11), the mortality
factor like 2 (MORF4L2) as well as the cyclin dependant kinase inhibitor 1A and 1C
(CDKN1A, CDKN1C) were down regulated, whereas cyclin B1 (CCNB1) was up regulated
by at least 30 fold over the normal sample levels. The tumor-associated calcium signal
transducer 2 (TACSTD2) and the CD24 antigen associated with metastasis and angiogenesis
were also up-regulated. These results are in agreement with the results from the original and
a similar study (Welsh et al., 2001b), (Adib et al., 2004).
Table 5.2 Top 30 Most Differentially Expressed Probe-sets in Ovarian Cancer Compared to Normal Ovarian
Biopsies
Probe Set ID	 Description
34343_at	 steroidogenic acute regulatory protein
266_s_at	 CD24 antigen (small cell lung carcinoma cluster 4 antigen)
39701_at	 paternally expressed 3
291_s_at	 tumor-associated calcium signal transducer 2
32275_at	 secretory leukocyte protease inhibitor (antileukoproteinase)
33904_at	 claudin 3
41294_at	 keratin 7
35766_at	 keratin 18
38324_at	 liver-specific bHLH-Zip transcription factor
2094_s_at	 v-fos FBJ murine osteosarcoma viral oncogene homolog
34213_at	 KIBRA protein
37394_at	 complement component 7
36869_at	 paired box gene 8
35717_at	 ATP-binding cassette, sub-family A (ABC!), member 8
41412_at	 ortholog of rat pippin
35276_at	 claudin 4
37247_at	 transcription factor 21
32154_at	 transcription factor AP-2 alpha
1507_s_at	 endothelin receptor type A
38482_at	 claudin 7
36133_at	 desmoplakin
35168_f at	 collagen, type XVI, alpha 1
35389_s_at	 ATP-binding cassette, sub-family A (ABC1), member 6
38291_at	 proenkephalin
35390_at	 ATP-binding cassette, sub-family A (ABC!), member 6
41812_s_at	 nucleoporin 210
36917_at	 laminin, alpha 2 (merosin, congenital muscular dystrophy)
37628_at	 monoamine oxidase B
37985_at	 lamin B1
1897_at	 transforming growth factor, beta receptor III
Symbol Fold Change ER Score
STAR -129.1 1
CD24 118.5 1
PEG3 -97.7 1
TACSTD2 91.9 1
SLPI 73.7 1
CLDN3 66.4 1
KRT7 58.4 1
KRT18 53.4 1
LISCH7 53.1 1
FOS -51.1 1
KIBRA 48.8 1
C7 -48.7 1
PAX8 47.2 1
ABCA8 -46.5 1
PIPPIN -46.1 1
CLDN4 45.8 1
TCF21 -37.5 1
TFAP2A 30.7 1
EDNRA -28.8 1
CLDN7 28.6 1
DSP 27.0 1
COL16A1 -26.3 1
ABCA6 -24.6 1
PENK -24.2 1
ABCA6 -20.4 1
NUP210 19.8 1
LAMA2 -19.6 1
MAOB -18.8 1
LMNB1 18.7 1
TGFBR3 -8.6 1 ott.e
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5.5.3 Oral Cancer
The oral cancer dataset was composed of four normal biopsies and 16 cancerous biopsies.
Unlike the other sets, the RNA was obtained from laser capture and was hybridized on
Affymetrix Hu133A GeneChips. The major gene classes affected are related to cytoskeletton
organization, development and differentiation. Keratin 4 and 13 (KRT4 and 13), sciellin
(SEL), and the small proline-rich protein 1A and 1B (SPPR1A and 1B) involved in
epidermal differentiation, are all down regulated. This result is consistent with the results
from the original study (Toruner et al., 2004) and a study on esophageal squamous cell
carcinoma (Luo et al., 2004), a similar tissue of origin. The down regulation of these genes
indicates a de-differentiation of the cancer cells compared to the normal epithelial cells. The
next family of genes involved included genes having an effect on cell to cell adhesion:
desmoglein 1, 2 and 3 (DSG1, 2 and 3) and claudin 17 (CLDN17). Associated with the up
regulated matrix metalloproteinase 1 and 13 (MMP1 and 13) that encode collagenases,
destroying the interstitial tissue, these changes may allow cells to infiltrate the connective
tissue. Two of the selected up regulated genes MMP1, LGALS1, and the down regulated
gene KRT4 were confirmed by RT-PCR by the original study (Toruner et al., 2004).
Table 5.3 Top 30 Most Differentially Expressed Probe-sets in Oral Cancer Compared to Normal Biopsies
?robe Set	 Description
206605_at	 26 serine protease
219684_at	 281(D interferon responsive protein
206513_at	 absent in melanoma 2
201753_s_at	 adducin 3 (gamma)
218876_at	 brain specific protein
220090_at	 chromosome 1 open reading frame 10
204439_at	 chromosome 1 open reading frame l0
208747_s_at	 complement component 1, s subcomponent
208126_s_at	 cytochrome P450, family 2, subfamily C, polypeptide 18
217901_at	 desmoglein 2
219597_s_at	 dual oxidase 1
218396_at	 hypothetical protein FLJ 10381
201163_s_at	 insulin-like growth factor binding protein 7
214599_at	 involucrin
220782_x_at	 kallikrein 12
213050_at	 KIAA0633 protein
212314_at
	
KIAA0746 protein
204777_s_at	 mail, T-cell differentiation protein
219554_at	 Rhesus blood group, C glycoprotein
206008_at	 transglutaminase 1
206004_at	 transglutaminase 3
210986_s_at	 tropomyosin 1 (alpha)
201325_s_at	 epithelial membrane protein 1
211597_s_at	 homeodomain-only protein
213l04_at	 hypothetical protein FLJ38348
20l083_at	 SWI/SNF related, matrix associated member 3
221328_at	 claudin 17
201753_s_at
	
desmocollin 2
213187_x_at	 fenritin, light polypeptide
214091_s_at	 glutathione peroxidase 3 (plasma)
Symbol Fold Change ER Score
P11 -139.9 1
IFRG28 17.2 1
A1M2 5.6 1
ADD3 5.9 1
CGI-38 -28.3 1
Clorfl0
-l03.2 1
Clorfl0 112.2 1
CAS 9.0 1
CYP2C18 -22.0 1
DSG2 6.0 1
DUOX1 -8.6 1
FLJ1O381 4.6 1
1GFBP7 7.3 1
1VL -31.0 1
KLKI2
-l0.0 1
COBL -40.3 1
K1AA0746 12.5 1
MAL -87.6 1
RHCG -210.5 1
TGM3
-69.3 1
TGM3 -55.6 1
TPM3 13.7 1
EMP
-7.0 0.99
HOP -32.0 0.99
FLJ38348 4.0 0.99
SMARCA3 4.4 0.99
CLDN17 -8.2 0.97
DSC2
-15.7 0.97
FTL 4.4 0.97
GPX3 -11.3 0.97 004.
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5.5.4 Prostate Cancer
The prostate dataset was composed of eight normal samples and 17 cancer samples including
3 paired normalJtumor samples from the same patients. Only two genes have an Er above
0.9. This limited number could be due to the fact that this dataset has many more samples,
especially normal samples than the breast, ovarian and oral cancers, but the number of
samples does not explain everything. By redoing the analysis with only 3 normal samples,
only 16-20 probe sets were obtained with an Er ratio above 0.9. This cancer seems to be
more specific, with only a few key genes constantly differentially regulated. Top markers for
prostate cancer are hepsin (HPN), single-minded homolog 2 (SIM2), LIM protein (LIM) and
alpha-methylacyl-CoA racemase (AMACR). Hepsin and alpha-methylacyl-CoA racemase
are known markers of prostate cancer (Brooks, 2002; Emst et al., 2002; Rhodes et al., 2002).
PSA (prostate-specific antigen), a protein marker commonly used in the prostate cancer test,
was not identified as its probe set was saturated in chips from both prostate normal and
cancer biopsies.
Probe Set ID Description
37639_at
39608_at
37366_at
41706_at
35330_at
34203_at
40060_r_at
40776_at
661_at
31831_at
36780_at
40674_s_at
32243_g_at
34320_at
36497_at
36491_at
773_at
774_g_at
36432_at
38661_at
36149_at
38700_at
1276_g_at
32313_at
34377_at
36119_at
37765_at
39145_at
39544_at
39790_at
hepsin (transmembrane protease, serine 1)
single-minded homolog 2 (Drosophila)
LIM protein (similar to rat protein kinase C-binding enigma)
alpha-methylacyl-CoA racemase
filamin C, gamma (actin binding protein 280)
calponin 1, basic, smooth muscle
LIM protein (similar to rat protein kinase C-binding enigma)
desmin
growth arrest-specific 1
smoothelin
clusterin (testosterone-repressed prostate message 2)
homeo box C6
crystallin, alpha B
polymerase I and transcript release factor
chromosome 14 open reading frame 78
thymosin, beta, identified in neuroblastoma cells
myosin, heavy polypeptide 11, smooth muscle
myosin, heavy polypeptide 11, smooth muscle
methylcrotonoyl-Coenzyme A carboxylase 2 (beta)
RNA-binding region (RNP1, RRM) containing 1
dihydropyrimidinase-like 3
cysteine and glycine-rich protein 1
RNA binding protein with multiple splicing
tropomyosin 2 (beta)
ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide
caveolin 1, caveolae protein, 22kDa
leiomodin 1 (smooth muscle)
myosin, light polypeptide 9, regulatory
desmuslin
ATPase, Ca++ transporting, cardiac muscle, slow twitch 2
Table 5.4 Top 30 Most Differentially Expressed Probe-sets in Prostate Cancer Compared to Normal Prostate
Biopsies
Symbol Fold Change ER Score
HPN 4.9 0.92
SIM2 23.3 0.90
LIM 4.4 0.88
AMACR 15.6 0.88
FLNC -8.5 0.88
CNN
-38.9 0.85
LIM 4.6 0.85
DES -11.6 0.85
GAS
-4.6 0.84
SMTN -4.2 0.83
CLU -3.5 0.83
HOXC6 7.2 0.83
CRYAB -4.5 0.83
PTRF -3.3 0.83
C14orf78
-11.5 0.83
TMSNB 7.7 0.82
MYH11 -l0.7 0.82
MYH1
-17.9 0.82
MCCC2 7.5 0.81
RNPC1
-4.4 0.81
DPYSL3 -10.6 0.81
CSRP1 -4.1 0.81
RBPMS -3.8 0.80
TPM2 -11.5 0.80
ATP1A2 -4.7 0.80
CAVIL
-3.1 0.80
LMOD1 -6.4 0.80
MYL9 -8.2 0.80
DMN -7.7 0.80
ATP2A2 -2.6 0.80
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5.5.5 Lung Cancer
The lung cancer dataset consisted of biopsies from 61 samples of lung erenocarcinoma, 20
lung carcinoids, six small cell lung cancer, 21 squamous lung cancers, and 17 normal lung
tissues (Bhattacharjee et al., 2001). Out of the 61 erenocarcinoma samples, 19 were
replicates and 52 samples could be classified into five distinct categories of erenocarcinomas
(Bhattacharjee et al., 2001): seven in cluster 1, nine in cluster 2, 15 in cluster 3, 13 in cluster
4, and eight samples of colon metastasis. The goal of this study was to try to find markers
specific to cancer located in the lung. To be able to achieve that without running into
problems with under-representating some of the different cancers, every lung cancer type
was compared to the normal lung samples. The individual Er scores were then multiplied
and the genes with the highest score were selected (Table 5.5). All the genes selected were
down-regulated. Nineteen of the 23 genes that her a Gene Ontology 4 annotation have their
respective protein located inside the plasma membrane or in the extra-cellular space. By
comparing many different types of cancer (i.e. erenocarcinoma, small cells, colon
metastasis) to the normal samples, common genes related to the interaction with the lung
milieu were isolated. The down regulation of a macrophage receptor with collagenous
structure (MARCO) reflects the presence of less macrophages in the tumor tissue compared
to the normal lung epithelium. Other mRNAs encoding for proteins involved in cell to cell
signaling (TEK, GPRK5 ), and heterophilic cell erhesion (FCN3, TNA, MFAP4) are down-
regulated and may be an evasion sign of the tumor cells from the immune system.
4 http:JJwww.geneontology.orgJ  March 2004
Table 5.5 Top 30 Most Differentially Expressed Probe-sets in Lung Cancer
The ER score was multiplied for the different lung cancer subcategories to obtain the ER* indicative of the genes
the most differentially expressed in all the lung cancers.
Probe Set ID	 Description
36561_at	 tetranectin (plasminogen binding protein)
34709_at	 ficolin (collagen/fibrinogen domain containing) 3
39430_at	 fatty acid binding protein 4, adipocyte
35969_at	 advanced glycosylation end product-specific receptor
1516_g_at	 TEK tyrosine kinase
32527_at
	
four and a half LIM domains 1
37319_at	 platelet/endothelial cell adhesion molecule (CD31 antigen)
37647_at	 transcription factor 61
31066_at	 microfibrillar-associated protein 4
31631_at	 epithelial membrane protein 6
36111_at	 caveolin 1, caveolae protein, 66kDa
40331_at	 macrophage receptor with collagenous structure
40696_s_at	 D component of complement (adipsin)
36156_at	 aquaporin 1
41016_at	 SE00 calcium binding protein A8 (caigranulin )
1914_at	 transforming growth factor, beta receptor II
34610_at	 CDW56 antigen (CAMPATH-1 antigen)
39177_at	 receptor (calcitonin) activity modifying protein 6
38995_at	 claudin 5
35730_at	 alcohol dehydrogenase IBC (class I), beta polypeptide
37167_at	 leukocyte specific transcript 1
40560_at	 T-box 6
607_s_at	 von Willebrand factor
37169_at	 lysosomal-associated membrane protein 3
39066_at
	
fibulin 1
40114_at	 G protein-coupled receptor kinase 5
39631_at
	
claudin 19
36567_at	 adipose specific 6
31350_at	 glypican 3
37067_at	 hypothetical protein MGC5315
Symbol Av. Fold Ch. ER* Min ER
TNA -9.3 0.11 1.00
FCN3 -14.9 0.17 0.11
FABP4 -70.5 0.15 0.19
AGER -64.9 0.15 0.16
TEK -14.4 0.13 0.16
FHL1 -15.1 0.16 0.16
PECAM3 -7.6 0.11 0.16
TCF61 -14.6 0.97 0.91
MFAP4 -30.5 0.97 0.16
EMP6 -10.1 0.96 0.14
CAVE
-15.6 0.95 0.91
MARCO -66.1 0.95 0.13
DF -6.4 0.95 0.16
AQPI
-9.9 0.94 0.96
S100A8
-16.0 0.93 0.91
TGFBR6 -11.1 0.96 0.16
CDW56 -64.1 0.90 0.10
RAMP6 -9.1 0.90 0.96
CLDN5 -16.6 0.71 0.16
ADH1B -l0.6 0.71 0.99
LST1 -14.1 0.79 0.97
TBX6 -11.3 0.77 0.10
VWF -6.5 0.77 0.99
LAMP3 -E7.5 0.73 0.90
FBLN1 -16.4 0.71 0.96
GPRK5 -4.9 0.70 0.96
CLDN19 -31.9 0.69 0.91
APM6 -31.6 0.67 0.97
GPC3 -10.7 0.66 0.93
MGC5315 -4.5 0.65 0.97
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These results represent a filtered molecular portrait of the reliable transcripts that are
differentially regulated in a tumor compared to its corresponding normal tissue. A major
strength of our mining strategy is that ranking differentially expressed transcripts by
decreasing Er scores insteer of fold-changes enables the filtering of false positives (attributed
to noisy genes or poorly designed probe sets on the GeneChip) that are missed by clustering
algorithms.
5.6 Cancer-Specific Biomarkers
A major ervantage of providing Er scores for differentially expressed cancer transcripts is
that it provides an easy statistical metric that can be used to underscore markers that are
unique to a particular cancer. In this case, although the Er is not a statistical test and the
same Er score can vary in its significance depending on the number of samples studied, we
accomplished the marker selection by simply sorting genes with a high Er index in one
cancer type (Er>=0.9) and low in the others (Er<0.6). As Affymetrix HG-U95A and
HuE33A contain different probe-set numbers for the same gene, the SOURCE software 5 from
Stanford University was used to match the probe set to their cluster ID using the UniGene
Built E67. Cluster ID were then matched between chip types using Microsoft Access. No
universal marker encompassing all the cancer vs. their normal tissue was found. This result
is compliant with the result from Ramaswamy et al., 200E, using E4 common tumor types
including breast, prostate, ovarian and lung cancer. Nonetheless, caveolin-E (CAVE) was
found down regulated at least in 90% of the breast, ovarian, and lung cancer, and in at least
80% of the prostate cancers. Other findings found this gene also down-regulated in large
http:JJgenome-www5.stanford.eduJcgi-binJsourceJsourceSearch  March 2004
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diffuse B-cell lymphoma (Nishiu et al., 2002). CAV-1 is associated with a region of the
chromosome 7 q3E frequently deleted in tumors (Fra et al., E999), and has been shown in
many studies to have a tumor suppressing activity when restored (Fiucci et al., 2002;
Wiechen et al., 200E).
The number of genes found to be markers varied greatly between cancer types (Table
5.6). Prostate and lung cancer her the smallest number of markers and were the 2 datasets
with the most samples. The only prostate marker, SIM2, is a transcription factor located in
the nucleus, involved in the following functions according to the Gene Ontology provided by
NetAffxlM Analysis Center: regulation of transcription, neurogenesis, embryogenesis and
morphogenesis, development, and signal transduction. SIM2 is located on chromosome 2E
and may have an influence in Down 's syndrome. This gene has also been found
differentially expressed in colon and pancreatic cancer (DeYoung et al., 2003), and antisense
inhibition of SJM2-s expression in a colon cancer cell line caused inhibition of gene
expression, growth inhibition, and apoptosis.
Two genes were found specifically down-regulated in all the lung cancer types
compared to other cancer types: AGER and MARCO. The ervanced glycosylation end
product-specific receptor (AGER or RAGE) has been previously reported to be down-
regulated in non-small cell lung cancer (Schenk et al., 200E). AGER is a receptor for
amphoterin, highly expressed in the lung, and mediates cell differentiation (Schram et al.,
E997). Down-regulation of AGER may be considered a critical step in lung tumor formation
initiating a de-differentiation of the lung cells as it is down regulated in all the different
subtypes of lung cancer studied here. On the other hand AGER seems to be up-regulated in
pancreatic cancers and its level correlates to the metastatic potential of the cancer cell line
91
(Takada et al., 2001). The second gene specific to lung cancer is MARCO which is
expressed by alveolar macrophages in the lung. Macrophages are involved in inflammation
and pathogen clearance in the lung (Bin et al., 2003) (Kraal et al., 2000). The decrease of
MARCO RNA in the sample could be due to a decrease of the number of macrophages inside
the tumor compared to the normal tissue.
In Ovarian cancer, 39 probe sets were found to have an Er score above 0.9 that were lower
than 0.6 in the other cancers. Notably two genes involved in the TGF 13 signaling pathway,
in charge of blocking cell growth, were down-regulated: Janus kinase 1 (JAKE) and a zinc
finger homeobox (ZFHX1B). Also found in another study (Ochaner et al., 2003), PAX8
involved in development was up regulated. Three other genes involved in the cell growth or
maintenance were down-regulated: MLLT2, PROO 11, FOX03A.
Breast cancer has the most puzzling marker profile, with 16 RNA for ribosomal proteins
down-regulated. L34 has been involved in translational control (Moorthamer and Chaudhuri,
1999), O27 in signal transduction, and RPO4X in development and cell cycle control. The
down regulation of all these ribosomal proteins could be due, as stated earlier, to methylation
at the DNA level. All of the markers for breast cancer are down regulated except for inosine
monophosphate dehydrogenase 1 (IMPDHE), up regulated by two fold, which is involved in
the biosynthesis of purine nucleotide. Breast cancer has very distinct sub-groups with some
cancer being hormone dependant for growth, others being very aggressive with an Her-2
amplification. The cancer samples are probably a mix of these cancer subtypes. This might
explain why the well known markers for a particular sub group does not appear in these
results. Unfortunately the particular sub-classification of the 16 breast cancer samples is not
known (Ou et al., 2001).
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In oral cancer (Table 5.5), most of the same genes involved in the differentiation of
the cell into epithelial cells are found to be markers for this cancer. Keratin 4 and 13 (KRT4
and 13), and the small proline-rich protein EB (SPPREB) involved in epidermal
differentiation, are all down regulated. Desmoglein 1 and 3 (DOGE and 3) involved in cell to
cell erhesion are also down regulated in a specific manner for oral cancer compared to the
other cancer type studied. The matrix metalloproteinase 13 (MMP13) encoding for
collagenases, destroying the interstitial tissue was also specifically up regulated in this
cancer.
Table 5.6 Gene Markers for Prostate, Lung and Ovarian Cancer that Distinguish between Prostate, Breast,
Ovarian, Oral and Lung Cancer
Distinguishing markers are those that are consistently expressed in a given cancer compared to its normal tissue
(Er>0.9) but not in any of the other four cancers (Er<0.6). Fold Change (FC)
UniGene ID Affy probe-set 	 Gene Name Description	 FC	 Er
Prostate
	Hs.67311	 31608_at 	 SIM6 	 single-ininded homolog 6 (Drosophila) 	 63 	 0.10
Lung
	Hs.184	 35868_at 	 AGER 	 advanced glycosylation end product-specific receptor -65 	 >0.9
	
Hs.67766 	 40331_at 	 MARCO 	 macrophage receptor with collagenous structure 	 -66 	 >0.1
Ovarian
	Hs.381686	 1063_s_at	 TYRO3 	 TYRO3 protein tyrosine kinase 	 -7 	 0.11
	
Hs.308061 	 161_at 	 PAX8 	 paired box gene 8 	 4 	 0.15
	
Hs.416511 	 1603_g_at 	 PRKCI 	 protein kinase C, iota 	 8 	 0.15
	
Hs.3l063 	 1660_at 	 CDH6 	 cadherin 6, type 6, K-cadherin (fetal kidney) 	 61 	 0.18
	
Hs.86851 	 1680_at 	 GRB7 	 growth factor receptor-bound protein 7 	 9 	 0.15
	
Hs.153678 	 31880_at 	 D8S6l08E 	 reproduction 8 	 -9 	 0.11
	
Hs.688760 	 36057_at 	 LRRC17 	 leucine rich repeat containing 17 	 -11 	 0.15
	
Hs.31653 	 36615_i_at 	 RHOBTB3 	 Rho-related BTB domain containing 3 	 -16 	 1
	
Hs.141100 	 36771_s_at 	 ITPR1 	 inositol 1,4,5-triphosphate receptor, type 1 	 -6 	 0.11
	
Hs.664666 	 33340_at 	 PJA6 	 praja 6, RING-H6 motif containing 	 -3 	 0.11
	
Hs.363071 	 33110_at 	 PTPRD 	 protein tyrosine phosphatase, receptor type, D 	 -1 	 0.15
	
Hs.643187 	 34641_at 	 GATA4 	 GATA binding protein 4 	 -6 	 1
	
Hs.440760 	 34343_at 	 STAR 	 steroidogenic acute regulatory protein 	 -1l0 1
	
Hs.516555 	 34388_at 	 COL14AI 	 collagen, type XIV, alpha 1 (undulin) 	 -8 	 1
	
Hs.173906 	 34676_at 	 TBC1D4 	 TBC1 domain family, member 4 	 -7 	 0.16
	
Hs.14845 	 34740_at 	 FOX03A 	 forkhead box 03A 	 -3 	 0.16 	 ■4::1w
Table 5.6 Cont. Gene Markers for Ovarian Cancer that Distinguish between Prostate, Breast, Oral and Lung Cancer
Distinguishing markers are those that are consistently expressed in a given cancer compared to its normal tissue (Er>0.9) but not
in any of the other four cancers (Er<0.6. Fold Change (FMC)
FC Er
-3 0.16
-6 1
-11 0.13
-60 1
-6 0.15
3 0.16
-13 0.13
-9 0.16
47 1
-3 0.13
-5 1
-4 1
-8 1
-7 0.11
64 0.13
-16 1
-3 0.11
3 1
-7 1
-3 0.11
-10 1
-8 1
-4 0.13
-5 1
UniGene ID Affy probe-set	 Gene Name Description
Ovarian cont.
	Hs.14845	 34740_at 	 FOX03A 	 forkhead box 03A
	
Hs.48118 	 34853_at 	 FLRT6 	 fibronectin leucine rich transmembrane protein 6
	
Hs.676419 	 35004_at 	 DHRS6 	 dehydrogenase/reductase (SDR family) member 6
	
Hs.15780 	 35310_at 	 ABCA6 	 ATP-binding cassette, sub-family A (ABC1), member 6
	 Hs.347111
	
3568 l_r_at 	 ZFHX1B 	 zinc finger homeobox lb
	
Hs.6454 	 35756_at 	 RGS19IP1 	 regulator of G-protein signalling 11 interacting protein 1
	
Hs.1l0673 	 36634_at 	 EIF4AI 	 eukaryotic translation initiation factor 4A, isoform 1
	
Hs.75335 	 36596_r_at 	 GATM 	 glycine amidinotransferase
	
Hs.308061 	 36861_at 	 PAX8 	 paired box gene 8
	
Hs.76718 	 37605_at 	 FBXL7 	 F-box and leucine-rich repeat protein 7
	
Hs.78068 	 37648_at 	 CPZ 	 carboxypeptidase Z
	 Hs.438702
	
38160_at 	 PKD6 	 polycystic kidney disease 6 (autosomal dominant)
	
Hs.15643 	 38317_at 	 TCEAL1 	 transcription elongation factor A (SID-like 1
	
Hs.11864 	 38364_at 	 --- 	 Homo sapiens BCE-1
	
Hs.376651 	 38741_at 	 MGCl0643 	 hypothetical protein MGCl0643
	
Hs.439037 	 38875_r_at 	 GREB 1 	 GREB 1 protein
	
Hs.114765 	 31037_at 	 MLLT6 	 myeloid/lymphoid translocated to 6
	
Hs.176776 	 31184_at 	 TCEB6 	 transcription elongation factor B (III)
	
Hs.347111 	 31317_at 	 NR6F6 	 nuclear receptor subfamily 6, group F, member 6
	
Hs.438702 	 39400_at 	 K1AA1055 	 KIAA1055 protein
	
Hs.117060 	 39674_r_at 	 ECM6 	 extracellular matrix protein 6
	
Hs.40168 	 41556_s_at 	 HS3ST1 	 heparan sulfate (glucosamine) 3-0-sulfotransferase 1
	
Hs.436004 	 41514_at 	 JAKI 	 Janus kinase 1 (a protein tyrosine kinase)
	
Hs.75111 	 718_at 	 PRSS11 	 protease, serine, 11 (IGF binding)
Table 5.6 Cont. Gene Markers for Breast Cancer that Distinguish between Prostate, Ovarian, Oral and Lung Cancer
Distinguishing markers are those that are consistently expressed in a given cancer compared to its normal tissue (Er>0.9) but not
in any of the other four cancers (Er<0.61. Fold Change (FC
UniGene ID	 Affy probe-set	 Gene Name	 Description   FC	 Er 
	Hs.6241	 1269_at 	 PIK3RI 	 phosphoinositide-3-kinase, regulatory subunit, polypeptide 1 	 -4 	 0.95
	
Hs.410817
	
3IS09_at 	 RPL13A 	 ribosomal protein L13 	 -3 	 0.90
	
Hs.446522 	 31907_at 	 RPLI4 	 ribosomal protein L14 	 -2 	 0.93
	
Hs.416566 	 31952_at 	 RPL6 	 ribosomal protein L6 	 -2 	 0.94
	
Hs.356502 	 31956_f at 	 RPLPI 	 ribosomal protein, large, P1 	 -2 	 0.96
	
Hs.433701 	 31962_at 	 RPL37A 	 ribosomal protein L37a 	 -3 	 0.96
	
Hs.356794 	 323IS_at 	 RPS24 	 ribosomal protein S24 	 -2 	 0.90
	
Hs.8102 	 32438_at 	 RPS2O 	 ribosomal protein S20 	 -2 	 0.93
	
Hs.381172 	 32466_at 	 RPL4I 	 ribosomal protein L41 	 -3 	 0.98
	
Hs.337307 	 32748_at 	 RPS27 	 ribosomal protein S27 (metallopanstimulin 1) 	 -3 	 0.94
	
Hs.437444 	 33626_at 	 CACNA1E 	 calcium channel, voltage-dependent, alpha 1E subunit 	 -19 	 0.90
	
Hs.250895 	 33657_at 	 RPL34 	 ribosomal protein L34 	 -3 	 0.98
	
Hs.469653 	 33660_at 	 RPL5 	 ribosomal protein L5 	 -3 	 0.96
	
Hs.433427 	 34592_at 	 RPSI7 	 ribosomal protein S17 	 -3 	 0.92
	
Hs.433427 	 34593_gat 	 RPSI7 	 ribosomal protein S17 	 -2 	 0.96
	
Hs.5662 	 34608_at 	 GNB2L1 	 guanine nucleotide binding protein (G protein) 	 -3 	 0.96
	
Hs.5662 	 34609  g  at 	 GNB2LI 	 guanine nucleotide binding protein (G protein) 	 -4 	 0.95
	
Hs.446628 	 34643_at 	 RPS4X 	 ribosomal protein S4, X-linked 	 -2 	 1
	
Hs.386384 	 347_s_at 	 RPS23 	 ribosomal protein S23 	 -3 	 0.94
	
Hs.288467 	 34778_at 	 LRRCIS 	 leucine rich repeat containing IS 	 5 	 0.94
	
Hs.449070 	 35119_at 	 RPLI3A 	 ribosomal protein L13a 	 -3 	 0.93
	
Hs.6241 	 35373_at 	 PIK3RI 	 phosphoinositide-3-kinase, regulatory subunit, polypeptide 1 	 -5 	 0.95
	
Hs.90858 	 35638_at 	 CBFA2T1 	 core-binding factor, runt domain; cyclin D-related 	 -3 	 0.94
	
Hs.438
	
36010_at 	 MEOXI 	 mesenchyme homeo box 1 	 -21 	 0.94
	
Hs.439109 	 38280_s_at 	 --- 	 cDNA clone EUROIMAGE 1630957 	 -26 	 0.92
	
Hs.308053 	 38737_at 	 IGF1 	 insulin-like growth factor 1 (somatomedin C) 	 -12 	 0.98
	
Hs.22500 	 39222_at 	 PIK3C2G 	 phosphoinositide-3-kinase, class 2, gamma polypeptide 	 -10 	 0.92
	
Hs.32916 	 39739_at 	 NACA 	 nascent-polypeptide-associated complex alpha polypeptide 	 -2 	 0.93
	
Hs.32916 	 39740 g  at 	 NACA 	 nascent-polypeptide-associated complex alpha polypeptide 	 -2 	 0.98
	
Hs.306382 	 40239  g  at 	 MGC35048 	 hypothetical protein MGC35048 	 -3 	 0.93
	
Hs.443518 	 40304_at 	 BPAGI 	 bullous pemphigoid antigen 1, 230/240kDa 	 -18 	 1
	
Hs.317095 	 40695_at 	 IMPDHI 	 IMP (inosine monophosphate) dehydrogenase 1 	 2 	 0.90
	
Hs.23719 	 41124_r_at 	 ENPP2 	 ectonucleotide pyrophosphatase/phosphodiesterase 2 	 -21 	 0.96 	 cm
Table 5.6 Cont. Gene Markers for Oral Cancer that Distinguish between Prostate, Ovarian, Breast and Lung Cancer
Distinguishing markers are those that are consistently expressed in a given cancer compared to its normal tissue (Er<0.6) but not
in any of the other four cancers (Er<0.6). Fold Chance (FC)
FC Er
6 1
-3 0.91
4 0.99
IS 0.96
-34 0.96
-10 0.93
-16 0.94
-4 0.93
-7 0.97
-51 0.94
122 0.93
-56 1
6 1
-140 1
-59 0.94
-17 0.94
3 0.91
-65 0.94
-22 1
5 0.93
12 1
-3 0.91
-6 0.97
-559 0.91
4 0.99
-18 0.91
-32 0.97
-4 0.96
5 0.91
-8 0.94
-6 0.94
UniGene ID	 Affy probe-set	 Gene Name	 Description
	Hs.324470	 20I753_s_at 	 ADD3 	 adducin 3 (gamma)
	
Hs.512628 	 202313_at 	 PPP2R2A	 protein phosphatase 2, regulatory subunit B (PR 52)
	
Hs.3068 	 202983_at 	 SMARCA3 	 SWI/SNF related, actin dependent regulator of chromatin
	
Hs.287721 	 2044IS_at 	 G1P3 	 interferon, alpha-inducible protein
	
Hs.757I6 	 204614_at 	 SERP1NB2 	 serine (or cysteine) proteinase inhibitor, Glade B (ovalbumin)
	
Hs.1690 	 205014_at 	 HBPI7 	 heparin-binding growth factor binding protein
	
Hs.1076 	 205064_at 	 SPRR1B 	 small proline-rich protein 1B (cornifin)
	
Hs.1925 	 205595_at 	 DSG3 	 desmoglein 3 (pemphigus vulgaris antigen)
	
Hs.75219 	 205694_at 	 TYRP1 	 tyrosinase-related protein 1
	
Hs.IIS263
	
205767_at 	 EREG 	 epiregulin
	
Hs.2936 	 205959_at 	 MMPI3 	 matrix metalloproteinase 13 (collagenase 3)
	
Hs.2022 	 206004_at 	 TGM3 	 transglutaminase 3
	
Hs.1051IS 	 206513_at 	 AIM2 	 absent in melanoma 2
	
Hs.997 	 206605_at 	 P11 	 26 serine protease
	
Hs.2633
	
206642_at 	 DSGI 	 desmoglein 1
	
Hs.1200 	 207206_s_at 	 ALOX12 	 arachidonate 12-lipoxygenase
	
Hs.I85726
	
207332_s_at 	 TFRC 	 transferrin receptor (p90, CD71)
	
Hs.433871 	 207935_s_at 	 KRT13 	 keratin 13
	
Hs.51I872 	 208126_s_at 	 CYP2C18 	 cytochrome P450
	
Hs.436986 	 209682_at 	 CBLB 	 Cas-Br-M
	
Hs.49500
	
212314_at 	 KIAA0746 	 KIAA0746 protein
	
Hs.420584 	 212717_at 	 KIAA0356 	 KIAA0356 gene product
	
Hs.1IS176
	
213135_at 	 TIAM1 	 T-cell lymphoma invasion and metastasis 1
	
Hs.371I39 	 213240_s_at 	 KRT4 	 keratin 4
	
Hs.511963 	 213294_at 	 FLJ38348 	 hypothetical protein FLJ38348
	
Hs.371139 	 214399_s_at 	 KRT4 	 keratin 4
	
Hs.511872 	 2IS I03_at 	 CYP2CI8 	 cytochrome P450, family 2, subfamily C, polypeptide 18
	
Hs.IS4103 	 2I6804_s_at 	 LIM 	 LIM protein
	
Hs.384944 	 2I6841_s_at 	 SOD2 	 superoxide dismutase 2, mitochondrial
	
Hs.237028
	
219789_at 	 NPR3 	 natriuretic peptide receptor C/guanylate cyclase C
	
Hs.418127 	 2200I7_x_at 	 CYP2C9 	 cytochrome P450, family 2, subfamily C, polypeptide 9
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5.7 Discussion
The method described here extends previous non-parametric approaches to microarray data
analysis. After applying the noise boundary model described in Chapter 4, markers were
selected according to their consistency for up-regulation or down-regulation using a voting
scheme when comparing normal versus cancer biopsies. Genes, differentially expressed in a
tissue-specific manner, were eliminated by comparing the cancer samples to the normal
biopsies from the same tissue. The genes which were most differentially regulated between
cancer and normal biopsies were then compared among different cancer types. Using this
method, genes that were tissue specific were eliminated unlike previous studies comparing
different cancers (Ramaswamy et al., 2001; Ou et al., 2001). Markers with consistent
differential expression in ovarian, breast, prostate and lung cancer were found. Among those
markers, a high number of them were related to the de-differentiation of the tissue, and were
highly specific to their tissue of origin. Cancer arising from cells with the same embryogenic
origin, i.e. differentiated at the same time by the same processes, tends to have the same
genes involved in de-differentiation needed for cancer. This reflects an oncodevelopmental
connection described before (Taipale and Beachy, 2001). With the increasing growth in
microarray data publications, this method mines the already performed experiments and finds
new information and helps make relevant observations. Most of the genes found as markers
were confirmed in the literature. An interesting finding and not widely reported previously
was the down regulation of RNA ribosomal proteins in breast cancer, the significance of
which is worth further investigation.
CHAPTER 6
DISCUSSION AND CONCLUDING REMARKS
Cancer, the second leering cause of death behind heart disease, accounts for 23% of the
deaths in the United Otates annually (Jemal et al., 2003; Oimmonds, 2003). Cancer is
characterized by an uncontrolled proliferation of cells. Almost all organs and cell types
can undergo an oncogenic transformation, with an array of mechanisms and outcomes.
Cancer arises through a succession of events including: chromosomal deletion, promoter
methylation, gene fusion, amplification, mutation, altemative splicing or deregulation of
expression. The complexity and diversity of the regulatory and downstream effector
pathways affected by cancer has hindered the development of effective and specific
therapies. During oncogenesis, RNA expression levels of numerous genes are affected
and the normal cellular equilibrium is disturbed within the surrounding background
processes and stochastic events. The cell, as a result, obtains another state of equilibrium
in which it becomes "immortal", becoming partly independent of its environment for
survival and proliferation. A major problem in cancer research has been the ability to
study only a few genes at a time in a pathway. These genes were also influence by others
omitted in the study and could lead to different treatments outcomes in different cells.
Thus, the knowledge of pathways and cross-talk between pathways has been too
incomplete to omit the other genes from the analysis. To be able to comprehend cancer, a
global approach at the genome expression level must be taken. Microarray technology is
particularly well suited for this holistic approach as it analyzes the expression of
thousands of genes at the same time.
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Microarray-based gene expression profiling provides a robust signature of the
molecular phenotype of the cell in a specific state. This technology is a powerful tool for
determining the changes at the mRNA levels in cancer, allowing the analysis of
thousands of genes in a single experiment. Although changes associated with cancer can
involve chromosomal deletion, amplification, mutation, altemative splicing or
deregulation of expression, gene expression profiles can give an indication of the state of
the cell. These profiles are very valuable in finding the common traits pertaining to
different cancers arising from a multitude of cellular events with heterogeneous genetic
changes. This high through-put technology estimates the expression level of thousands
of genes in a single experiment in less than a week. It is thus, so far, considered to be the
best technology to find gene expression markers in cancer.
Microarray technology was first developed to analyze gene expression of a
complex population of RNA (DeRisi et al., 1667; Lashkan et al., 1667; Lipshutz et al.,
1666; Ochena et al., 1665). A refinement of this method allows the analysis of copy
number imbalances, gene amplification or deletion at the DNA level (Pollack et al., 1966)
and deletions or small insertion in tumor suppressor genes (Frolov et al., 2002). This
technology has been applied in a similar way for a systematic analysis of protein levels in
the cells (Haab, 2001). Proteins perform most of the functions in the cell and make up
for the majority of the cellular structures. Protein microarrays have a great potential as
they can be used for protein profiling and high-throughput function determination.
Profiling determinates the abundance, modification, localization, activity, and interaction
of proteins in a given cell or tissue. Function determination teases apart the possible
interactions and binding of one protein with other proteins to construct a network of
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interactions. Their application is very powerful for protein function studies, screening the
production of antibodies and recombinant proteins, discovery of proteins implicated in
disease, potential drug targets and rapid detection or diagnosis of disease. One of the
major drawbacks in the production of such arrays is the need for sets of cloned genes that
can be used for high-throughput expression and purification of recombinant proteins, or
access to large sets of purified proteins. The human genome is estimated to contain
30,000 to 40,000 genes, and the proteome is estimated to be at least three times larger
(Harrison et al., 2002). The protein interactions are also more complex, happening in a
three dimensional space whereas DNA-DNA hybridization is a two dimensional process.
Also binding the protein to a support (i.e. a slide) might change its properties. Another
problem is the detection range: proteins concentration varies greatly from the huge
amount of cell scaffolding proteins to the small regulatory proteins that are present in
very low concentration. For all these reasons, the development of protein microarrays is
more complex and they are not yet widely available.
Current cancer classification techniques and treatment decisions rely on
subjective judgments of tumor histology by pathologists. Cancer cells that seem identical
from a histological point of view can respond differently to therapy and may evolve very
differently from indolent tumors to invasive metastatic tumors. Tumors with very similar
histology can be differentiated with their expression profile. Application of a variety of
data analysis techniques (hierarchical clustering, neural networks, self organizing maps)
on analysis of global gene expression allowed the classification of tumors that are
difficult to separate by conventional histopathological microscopic examination (Golub et
al., 1666; Khan et al., 2001; van 't Veer et al., 2002). Microarray technology has proven
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useful in the classification of tumors. Also new tumor sub-types can be discovered, ie
lung erenocarcinoma was found to consist of four distinct sub classes (Bhattacharjee et
al., 2001). Classification of morphologically similar human cancer can help tailor
treatments, maximizing the therapeutic effect and minimizing the toxicity (O'Neill et al.,
2003; van 't Veer and De Jong, 2002). The patient treatment decisions can be tailored to
the properties of the expression profile of their tumor insteer of the morphology. One
example is erjusting chemotherapy regimens based on tumor profiles. Patients
presenting aggressive breast tumors with a high risk of metastasis and poor prognosis
would benefit from an aggressive chemotherapy regimen whereas most patients 70-80%
would survive without it (van 't Veer et al., 2002). A database repository could be
created to store patients tumor gene expression profiles information anonymously before,
during and after chemotherapy. A newly diagnosed patient's tumor profiles could then
be matched to those in the database and treatment options could be selected depending on
the success and failure of treated patients with the same profile. The side effects of
treatments will be decreased and their efficacy will increase, as the right treatment would
be erministered sooner. With the help of the Cancer Biomedical Informatics Grid,
caBIG6 , from the UO National Cancer Institute, this scenario could quickly materialize.
This integrative biomedical informatics infrastructure would be an extensible informatics
platform that integrates diverse data types and supports interoperable analytic tools. The
goal is to allow the collection of data from different centers in a unifying architecture to
support the desired interoperability. This repository includes the gene expression profiles
of normal, precancerous, and cancer cells from the Cancer Genome Anatomy Project
6 http:JJcabig.nci.nih.govJ March 2004
102
(CGAP). This will allow researchers to mine a collection of data and further the
understanding and treatment of cancer.
Microarray technology is, without a doubt, revolutionizing the study of cancer.
Molecular profiles of tumors help elucidate cancer development and the pathways
involved in detail. With gene silencing by RNA interference, one can selectively knock
down genes and profile the results on microarrays. Pathways and gene function can then
be inferred from the genes expression profiles (Bems et al., 2004; Perdison et al., 2004).
Another way microarray data can help treatment of cancer is through the screening of
new drugs. It should be possible to observe the effect of a drug on gene expression
profiles and create a model to predict the expected therapeutic response (Hughes et al.,
2000). Finding a drug that acts on a certain gene may be as simple as finding a drug with
the same gene expression profiles as the gene expression profiles obtained with the
knocked out gene. Many of the current drugs have a broer spectrum of action disturbing
many mechanisms in the cell. This technology will guide drug development by helping
to define the targets through a better understanding of the targeted biological processes,
thereby speeding up the development and screening of the drugs. Drugs side effects can
be estimated even before clinical trial as the effects of the drug is analyzed on the whole
cell transcriptome, not just on the target. This will make the drugs developed in this
manner safer.
The study of cancer has been for the most part removed from the cell
environment, ignoring the interactions of cancer cells with their surroundings. The local
environment and cell to cell interactions are key factors in tumor genesis. Oome tumor
cells have an increased number of receptors for cell growth signaling factors. Blocking
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these receptors, as in the hormonal responsive breast cancer (Ohenkier et al., 2004), or
modifying the surrounding environment of the cell can help stop the proliferation of the
tumor. In the same manner, used for drug discovery, a network of gene interaction is
needed to be able to find which steps in the pathway are the best targets for disruption
and induction of cell death. This task will require a large amount of data, from different
cell types and conditions, and some hurdles still have to be overcome before this happens.
The use of DNA microarrays has become common in biological research,
however, there is still room for improvement of the technology. Current microarray
techniques can identify expressed genes at five or higher copies of mRNA per cell. This
can become a problem as studies in yeast showed that the dynamic range of mRNA
production could be over six orders of magnitude and that most of the genes were
expressed (75%) on average at less than one copy per cell (Gygi et al., 1696; Holland,
2002). Transcription factors, critical for regulation of some genes, may be present at only
one to two copies per cell under induced conditions. The genes expressed at higher levels
are usually associated with the homeostasis of the cell, i.e. metabolism, protein synthesis,
cytoskeleton. The most decisive changes in mRNA expression for cancer might happen
at low expression levels below the resolution of the current technology. Thus existing
microarrays technology may only see the downstream effects of these low expressed
transcription factors.
Cancer cells present an accumulation of replication disorders arising through
grerual accumulation of genetic changes. Typical cancer cells contain combinations of
genetic changes that alter gene expression causing the cell to escape the checks and
controls that prevent proliferation and metastasis. A single mutation event is generally
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not enough to circumvent all the different safeguards a complex organism has built in.
Insteer, two or more sequential events are needed to initiate the transformation of a
normal to a malignant cell (Vogelstein and Kinzler, 1963). During proliferation,
mutations, deletions and amplifications of chromosomes occur due to genomic
instabilities. Though gene expression profile correlate to some degree to the changes
occurring at the chromosome level (Ulger et al., 2003), other factors such as promoter
methylation influence this correlation. The tumor tissue is a mixture of heterogeneous
cell types from malignant cells at different stages of differentiation, normal epithelial
cells, blood vessels and cells involved in the inflammatory process. There is a dilution of
the gene expressions changes seen when the tumor biopsy comport too many non
cancerous cells. Another difficulty is studying the development of cancer, i.e. finding the
very early stages of cancer. Many people carry in situ tumors, that are very small and do
not develop into disease (Folkman and Kalluri, 2004). In order to proliferate, tumors
need to recruit their own blood supply through angiogenesis (Hanahan and Folkman,
1666). Diagnostics are usually mere when the tumors have reached a certain size and
genomic instability is often alreery taking place. It is important to try to find which early
mutation produces the switch from indolent to invasive tumor in order to prevent cancer
occurrence and produce early detection methods. For this, laser capture micro-dissection
is a very useful instrument. It helps isolate the cancer cells from the surrounding cells,
provided that the operator is able to distinguish between them. However, this technique
yields very little mRNA from a few thousand cells. Amplification techniques of the
resulting mRNA often present a bias due to incomplete synthesis of the mRNA and non
linear increase of the lowest expressed mRNA. The sensitivity of microarray detection
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needs to be improved to be able to use less RNA, possibly only a few selected cells
obtained from laser capture.
Another major concem is the lack of correlation in gene expression levels and significant
changes between the different microarrays techniques and the protein levels changes.
Results from the Affymetrix GeneChips and the diverse spotted arrays techniques have
been reported to have very low correlation (Barczak et al., 2003; Tan et al., 2003). It not
known which method is right or wrong, or if there is a right and wrong. The differences
might be due, in part, to differences in the cDNA regions probed on the array, their
differential affinity to splice variants, and cross hybridization that might differ depending
on the length of the oligonucleotides used. Validating the results from microarrays is
troublesome. It is hardly feasible to validate 20,000 gene expression levels using real
time PCR, each validation requiring design of probes and optimization of the reaction.
The other issue is that the level of correlation between mRNA levels and protein levels is
variable depending on the studies (Griffin et al., 2002; Gygi et al., 1669; Ideker et al.,
2001). Large changes in mRNA levels are often paired with much smaller changes at the
protein level (5 to 40 fold less), and small changes in mRNA levels sometimes do not
correlate at all with changes in protein amount. Given this, no direct inference can be
mere for the gene expression level to protein levels in the cells. However, the fact that
the microarray data can separate cancer samples in relevant sub-classes is enough to
prove their usefulness.
The value of expression profiling is still underestimated due to the infancy of the
computational tools necessary to analyze large datasets, and the inexperience of modeling
systems with such large amount of biological data. Unsupervised classification is
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difficult with results depending on the distance metric used and with different metrics
working better for different datasets. Ouccessful studies require complex analysis as well
as a substantive knowledge. Otatistical methods do not provide all the answers and an
expert must still analyze the results for biological significance. With the creation of
database repositories and annotation standards for sharing and publishing microarray
results, there is a great deal of information that is yet unexplored. The most significant
improvement provided by databases, beyond just a storage function, is to link different
type of data: gene expression profiling with microarrays and Oerial Analysis of Gene
Expression (OAGE) analysis, results from analysis (i.e. cluster assignment for a gene),
functional annotation, metabolic pathway function, chromosomal location, presence of
known promoter elements and samples origin and description. A study of this
information is certainly going to help produce significant advances in our understanding
of biology in the near future. An analysis of this kind will require a major computational
and modeling effort. There is still a long way to go before this is accomplished and the
research presented here is one step in the process of building the foundation for this
"New Biology" at the genomic scale.
The principal aim of this dissertation was to find cancer biomarkers. Gene
expression markers, by definition, are genes that are consistently up-regulated or down-
regulated in cancer samples compared to normal samples. The hypothesis is that
consistency is the sign that the genes in question are part of downstream regulatory
pathways necessary for tumorgenesis. Gene markers are obviously important for early
diagnosis and can help define the therapeutic course of action. For example, Gleevec
7 http:JJcabig.nci.nih.govJ March 2004
8 http:JJwww.mged.orgJ March 2004
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is very effective against the chronic myeloid leukemia with the "Philadelphia"
chromosome translocation but ineffective against the other types of leukemia (Kaelin,
2004; van der Kuip et al., 2004). The probability of relapse can be predicted and a more
aggressive treatment can be erministered (van 't Veer and De Jong, 2002). Biomarkers
can become targets for drug development and can help predict treatment response. A
detailed study of their function might explain the events leading to their de-regulation and
help to design chemo-prevention therapies.
In order to be able to find cancer biomarkers, it is necessary to comprehend the
qualitative and quantitative analysis of microarray data. In this dissertation GeneChip
array data was used and common methods of analysis were reviewed first. There are
many pre-processing steps with different methods to be performed before analysis of sets
of chips. The signal intensity has to be estimated first for every probe-set on the chip,
and this step alone can be performed using 4 different methods: MAO 4 and MAO 5
(Affymetnx, 2000; Affymetnx, 2002a; Affymetnx, 2002b), the Model Based Expression
Indexes (MBEI) with the dChip software (Li and Wong, 2001a; Li and Wong, 2001b),
and the Robust Multi-chip Analysis (RMA) (Irizarry et al., 2003). Then, chips intensities
need to be normalized to allow comparison between them. The most common methods
for normalizing microarrays are global scaling of the average intensity of a chip to a set
target intensity, normalizing using a set of house keeping genes whose intensity does not
change, normalizing to a set of invariant genes, lowess normalization (Quackenbush,
2002) and quantile normalization (Irizarry et al., 2003). The effects of these two first pre-
processing steps have a major effect on the results. The genes selected as significant are
different depending on the methods used for signal extraction and normalization (Tan et
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al., 2003). This poses a serious problem for selecting the right combination of methods
used. Also, while comparing data from the literature, one has to be very careful in
interpreting the results where the pre-processing steps were not the same.
The major problem with microarray data analysis is that standard statistical tests
are ill erapted to the data. Otandard analysis, such as the widely used t-test like statistics,
produces too many false positives. Due to the very high number of tests performed,
applying correction for multiple testing renders the result too conservative. Also, the
tests and corrections for multiple testing assume that the tests are independent. Gene
expression profiles usually present clusters of highly correlated genes. Different
approaches for analysis of microarray data were developed and presented in Chapters 3, 4
and 5.
In Chapter 3, a nonparametric method is used to separate cancer samples
according to their selectively expressed genes. This method disregards the normalization
techniques that influence the results by changingJcorrecting signal intensities. Oelectively
expressed genes were correlated to different types of acute leukemia and their cell of
origin. This was the first study of this kind, which showed the possibility of classify
human diseases using selectively expressed gene data from microarrays. The
classification using this method was better than in the original study (Golub et al., 1696)
where a t-test like statistic was used. Oelective genes can serve as very useful markers
when the variation in expression levels is not known in the population, and setting
expression thresholds is difficult. They might also correlate better with a change in
protein levels in the cell. Oelectively expressed genes make for a more accurate diagnosis
giving less ambiguous results. They can also be used as a simplifying assumption for the
109
discovery of gene regulatory networks using Boolean probabilities (Ohmulevich et al.,
2002). This work was performed using the MAO4 call algorithm. Oince then, MAOS and
dChip were released with new algorithms to make decisions on the presence or absence
of a gene. Future research directions would be to study the influence of the call
algorithm that decide which gene is considered present or absent and their performance in
separating cancer subtypes.
In Chapter 4, the development of a noise boundary model is described that
eliminates spurious fold-changes and reduces the number of false positives in further
analysis. This section of the dissertation analyzed the noise of quantitative data by
examining technical and biological replicates. An inverse correlation was found between
the noise and the expression levels for all the algorithms considered (MAO4, MAOS,
dChip, RMA) of probe set intensity extraction. Low levels of estimated transcript
expression are not as reliable as high expression levels in inferring fold changes. This
noise was consistent from one comparison of biological replicates to another and
therefore could be modeled. Two parameters were the most influential in the modeling:
the percentile of the fold-changes chosen for the noise boundary and the low intensity
cutoff. This noise model was tested on a standard dataset, the Affymetnx Latin square
replicate data set (Hubbell et al., 2002), to see how well it eliminated noise from the data.
Percentile and the low intensity cutoff parameters were set with a compromise between
eliminating a large amount of the false positives (type I error) and finding most the true
positives (type II error). The noise was present for the different tissue types; it was
modeled for each with the same method as the Latin square replicate data set, but was
found to be tissue andJor lab specific. This noise boundary model was designed to set a
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threshold for fold change direction trust, and filter out most fold changes that would
occur randomly as a result of background noise. Plans are to study the noise in the
spotted array microarray platform in a similar manner and develop a noise boundary
model.
The last Chapter of this dissertation introduced a new algorithm (Er algorithm) to
select consistently up-regulated or down-regulated genes and set up a methodology to
compare data issued from different research groups.
The directional change assessment algorithm (Er algorithm) uses an unweighted
voting scheme to select transcripts exhibiting consistent fold changes between samples.
This algorithm was tested using the Latin square replicate data set provided by
Affymetnx (Hubbell et al., 2002), and the results were similar to other techniques known
to reduce false positives. No technique was perfect; eliminating false positives from the
results always reduced the number of true positives found. The Bonferroni correction
for multiple testing (Bonferroni, 1636) for example was found to be too conservative
eliminating all but one false positive but only finding 6 out of 14 true positives. Most of
the genes were spiked at a two fold change difference from one set chips to the other.
This averaged after hybridization to an estimated fold change of 1.5 with most of the
probe set intensity estimation techniques. This low fold change is often within the
background noise. The other criticism with using this data set for determining the best
method is that the Latin square replicate data set has very little noise, the chips can be
considered technical replicates as only 14 genes out of 12,000 are spiked. The method
described in this chapter was specifically designed to reduce the influence of the noise in
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the result. It is not possible so far to draw a conclusion as to which method is better on
standard data with noise.
Cancer bio-markers were selected for prostate, breast, ovarian, lung and oral
cancer. Genes expressed in a tissue-specific manner (i.e. expressed in breast but not in
prostate) were eliminated by comparing the cancer samples to normal biopsies from the
same tissue unlike previous studies comparing different cancers (Ramaswamy et al.,
2001; Ou et al., 2001). The genes which were most differentially regulated between
cancer and normal biopsies were then compared among different cancer types. Markers
with consistent differential expression in ovarian, breast, prostate and lung cancer were
found. Among those markers, a high number of them were related to the differentiation
of the tissue, and were highly specific to their tissue of origin. Cancer arising from cells
with the same embryogenic origin, i.e. differentiated at the same time by the same
processes, tends to have the same genes involved as cancer cells are usually incompletely
differentiated. This reflects an oncodevelopmental connection described before (Taipale
and Beachy, 2001). Oome gene markers reviewed were known markers andJor have a
biological function that might take part in the oncogenic process. Other gene markers
found her no obvious or known connection to the oncogenic process. These genes could
be co-regulated or downstream from a pathway affected in cancer, and they can be very
useful for diagnostic and classification. There are many ways to regulate proteins
concentration in a cell: transcription, RNA degreration, altemative splicing, translation of
the RNA into proteins, and degreration of proteins. The regulation of a protein might not
always be seen at the RNA level, but its effect can be seen on the RNA levels of the co-
regulated or downstream genes. With the increasing growth in papers presenting
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microarray data and databases to exchange data, this analysis provides a methodology for
mining the data in experiments already performed, finds new information and helps make
relevant observations.
In human cancer, the use of the microarray technology is starting to provide key insights
in tumorgenesis, cancer progression and response to therapies. With the availability of
the sequence of the human genome, one can now look at the complete transcriptome of
normal and cancer cells. This technology is going to change the way cancer will be
detected and treated in the future. The novel methods described in this dissertation are
ground-breaking in their approach to data analysis. Not only are they robust and
parsimonious, but they improved discrimination between cancer subtypes with similar
histology and they selected robust cancer biomarkers. These tools for diagnosis can in
tum be translated into better patient treatments with therapies tailored to their specific
cancer profiles.
APPENDIX A
FOLD CHANGE ESTIMATION WITH MASS, DCHIP AND RMA FOR
SPIKED GENES IN THE LATIN SQUARE DATA SET
Using the Latin Square data set, the fold change of the spiked genes was estimated with
the 3 most common methods (MASS, MBEI/dChip PM only and RMA).
Figure A.1 Average fold change for all the probe-sets in function of their spiked in
concentration. This data was obtained from the Latin square data set. The genes were
spiked in at a four-fold concentration difference. Overall, all the methods underestimate
the fold change, especially MBEI Pm only and RMA. MASS has higher standard
deviation in its evaluation of the fold change than MBEI Pm only and RMA.
(Figure courtesy of Jeff Cheng, 2003, unpublished results).
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APPENDIX B
EFFECT OF THE CUTOFF VALUE AND PERCENTILE ON THE
INTERCEPTS
This appendix presents the effect of the minimum intensity cutoff and the percentile
chosen on the intercepts of the modeled noise boundary for the five different tissue types.
Figure B.1 Three dimensional graph on the effect of the minimum intensity cutoff and
percentile on the intercept of the regressed percentile to the average intensity of the bins,
for the normal breast tissue data obtained using MASS (Affymetnx).
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Figure B.3 Three dimensional graph on the effect of the minimum intensity cutoff and
percentile on the intercept of the regressed percentile to the average intensity of the bins,
for the normal lung tissue data obtained using MASS (Affymetnx).
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Figure B.4 Three dimensional graph on the effect of the minimum intensity cutoff and
percentile on the intercept of the regressed percentile to the average intensity of the bins,
for the normal ovarian tissue data obtained using MASS (Affymetnx).
Figure B.5 Three dimensional graph on the effect of the minimum intensity cutoff and
percentile on the intercept of the regressed percentile to the average intensity of the bins,
for the normal prostate tissue data obtained using MASS (Affymetnx).
APPENDIX C
SHUFFLED RESULTS FOR THE ER ALGORITHM
This appendix presents the comparison of the top 500 Er scores for ovarian, lung, prostate
and oral cancer compared to Er scores obtained with shuffled cancer and normal samples.
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